

Referenser 2019

Innehållsförteckning

Allergi.....	2
Astma och KOL	2
Endokrinologi.....	3
Fetma.....	5
Gynekologi.....	6
Hjärt- och kärlsjukdomar	8
Hud.....	12
Infektionssjukdomar.....	16
Kognitiva sjukdomar	17
Lipidrubbing	18
Matsmältningsorgan	20
Munhålan	22
Neurologi.....	25
Osteoporos.....	28
Psykiatri	30
Smärta.....	35
Tandvårdslistan	37
Urologi	40
Äldre – särskilda rekommendationer	41
Öron.....	43

Referenser Allergi

<https://www.euroforea.eu/aria>

Referenser Astma & KOL

1. www.lakemedelsverket.se Behandlingsrekommendationer: Läkemedelsbehandling vid astma
2. www.lakemedelsverket.se Behandlingsrekommendationer: Läkemedelsbehandling av kroniskt obstruktiv lungsjukdom (KOL)
3. <http://www.socialstyrelsen.se/nationellariktlinjerastmaochkol>
4. <https://ginasthma.org/>
5. <http://goldcopd.org/>
6. <http://www.barnallergisektionen.se/> välj "Riktlinjer/riktlinjer allergi" / punkt D10

Symtomskattningsformulär:

7. <http://www.catestonline.org/images/pdfs/SwedenCATest.pdf>
8. <https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-dyspnoea-scale-mrc-breathlessness-scale/>
9. www.ccq.nl

Referenser Endokrinologi

Nationella dokument

- Socialstyrelsens Nationella riktlinjer för diabetesvård, 2017/2018. <http://www.socialstyrelsen.se/nationellariklinjerfordiabetesvard>
- Egna mätningar av blodglukos vid diabetes utan insulinbehandling. SBU rapport 2009.
- Nationella diabetesregistret (NDR) 2017.
- Läkemedelsbehandling vid typ 2-diabetes – ny behandlingsrekommendation 2017 <https://lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/Information-fran-lakemedelsverket-nr-4-2017-behandlingsrekommendation.pdf>
- Kost vid diabetes. Socialstyrelsen 2011, www.socialstyrelsen.se
- Att förebygga aterosklerotisk hjärt-kärlsjukdom med läkemedel. Information från Läkemedelsverket 5:2014, www.lakemedelsverket.se

Prevalens – Incidens

- Jansson Sp et al. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. *Diab Med.* 2015;23(10):1319-28.
- Diabetes - a global threat. *Lancet* 2009;373:1735.

HbA1c

- Bjellerup P, Nordin G, Jeppsson JO. Genomförande av IFCC-kalibreringen för HbA1c – rekommendationer från SFKK och EQUALIS. *DiabetologNytt* 2010;23:95-99

Klassifikation – behandlingsgrunder

- Gale EA. Latent autoimmune diabetes in adults: a guide for the perplexed *Diabetologia* 2005;48:2195-9.
- Karlsson E et al. MODY - en autosomt dominant form av diabetes. Diagnos via gentestning ger bättre behandling. *Läkartidningen* 2007;104:2600.

Fysisk aktivitet

- FYSS 2015
- Tuomilehto J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *New Engl J Med* 2001;344:1343-50.
- Ramachandran A et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia* 2006;49:289-97.
- Diabetic prevention program research group. Reduction in the incidence of type 2 diabetes with life style intervention or metformin *New Engl J Med* 2002;346:393-403.
- Cederholm J et al. Samband mellan risk-faktorer och komplikationer vid diabetes. Rapport efter 13 år med Nationella diabetesregistret (NDR). *Läkartidningen* 2009;106:2684.
- The Look AHEAD Research Group. *NEJM* 2013;369:145-154

Multifaktoriell behandling – blodsocker, lipider, blodtryck

- The diabetes control and complication trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *New Engl J Med* 1993;329:977-86.
- UK prospective diabetic study (UKPDS) group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. *Lancet* 1998;352:837-53.
- Stratton M et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321:1405-12.
- Holman RR et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. *New Engl J med* 2008;359:1565-76.
- UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. *Lancet* 1998;352:854-65.
- Gaede P et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *New Engl J Med* 2003;348:383-93.
- Gaede P et al. Effect of Multifactorial Intervention on Mortality in Type 2 Diabetes. *New Engl J Med* 2008. 358:580-91.

Riktvärden för behandlingsmål

- The ACCORD Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. *New Engl J Med* 2008;358:2545-59.
- The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med* 2008;358:2560-72.

- Skyler JS et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. *Diabetes Care* 2009;32:187-192
- Fors P. Dagens målvärden vid diabetes inte självklara för äldre-äldre. *Läkartidningen* 2009;106:1639
- Tema Diabetes typ 2 *Läkartidningen* 2018;115:EX4W. 345-373.
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes: www.nejm.org/doi/full/10.1056/NEJMoa1504720 Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes: www.nejm.org/doi/full/10.1056/NEJMoa1603827 Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes: www.nejm.org/doi/full/10.1056/nejmoa1607141

Hypoglykemi

- Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. *Diabetologia* 2002;45:937-48.

Behandlingsstrategi vid typ 2 diabetes

- UK prospective diabetes study (UKPDS) group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patient with type 2 diabetes. *Lancet* 1998;352:837-53.
- National Institute for Health and clinical excellence. Type 2 diabetes – newer agents. <http://www.nice.org.uk> Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes. *Diabetes Care* 2012;35:1364-1379
- Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New Engl J Med* 2015. 373: 2117-28
- Marso PM et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New Engl J Med* 2016. 375:312-22
- Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *New Engl J Med* 2017. 377:644-657

Injektionshjälpmedel, Egenmätning av blodglukos

- Defronzo, R., Ferrannini, E., Zimmet, P., Alberti, G. (2015). *International Textbook of Diabetes Mellitus*: Wiley-Blackwell
- Ekman, I., red. (2014). *Personcentrerad inom hälso-och sjukvård: Från filosofi till praktik* Stockholm: Liber.
- Frid, AH., Kreugel, G., Grassi, G., Halimi, S., Hicks, D., Hirsch, LJ., Smith, MJ., Wellhoener, R., Bode, BW., Hirsch, IB., Kalra, S. & Strauss, KW. (2016). New Insulin Delivery Recommendations. *Mayo Clin Proc.* 91(9):1231-55. doi: 10.1016/j.mayocp.2016.06.010

Hypotyreoos

- Allahabadi A et al. Diagnosis and treatment of primary hypothyroidism. *BMJ* 2009;26:338
- Nygaard B et al. Effect of combination therapy with thyroxine (T4) and 3,5,3'-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. *Eur J Endocrinol.* 161:895-902.
- Nyström E et al. Vanligt, kvinnligt och lättbehandlat. Om primär hypotyreoos – en okänd folksjukdom. *Läkartidningen* 2003;8:610-617

Testosteron

- Bhasin S et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010;95:2536-59. Review
- Corona G et al. Update in testosterone therapy for men. *J Sex Med* 2011 Mar;8:639-54; Review
- Nigro N, Christ-Crain M. Testosterone treatment in the aging male: myth or reality? *Swiss Med Wkly.* 2012
- Wu FC et al. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med* 2010 Jul 8;363(2):123-35

D-vitamin

- D vitamin Lorentzon M et al. D-vitaminbehandling och skeletthälsa – svenska riktlinjer behövs. *Läkartidningen* 2014;111(37):1508-1510

Sekundär binjurebarksinsufficiens

- Calissendorf J. Sekundär kortisolbrist – ett inderdiagnostiserat tillstånd. *Läkartidningen* 2007.104:2965-68

Referenser Fetma

Vårdprogram för vuxna:

- lång version:

<https://vardgivare.skane.se/vardriktlinjer/medicinska-omraden/endokrina-organ-fetma-och-diabetes>

- kortversion:

<https://vardgivare.skane.se/vardriktlinjer/medicinska-omraden/endokrina-organ-fetma-och-diabetes/ako/overvikt-och-fetma-hos-vuxna/>

Vårdprogram för barn och ungdomar:

- lång version:

<https://vardgivare.skane.se/vardriktlinjer/medicinska-omraden/endokrina-organ-fetma-och-diabetes>

- kort version:

<https://vardgivare.skane.se/vardriktlinjer/medicinska-omraden/endokrina-organ-fetma-och-diabetes>

Mödrahälsovården:

- Regionala riktlinjer inom mödrahälsovården för övervikt och fetma under graviditet:

<https://vardgivare.skane.se/siteassets/1.-vardriktlinjer/regionala-riktlinjer---fillistning/overvikt-under-graviditet--riktlinje-2017-05-24.pdf?highlight=graviditet+%c3%b6vervikt>

- Regionala riktlinjer för kvinnor inom mödrahälsovården som genomgått gastric by-passoperation:

<https://vardgivare.skane.se/siteassets/1.-vardriktlinjer/regionala-riktlinjer---fillistning/regionala-riktlinjer-for-modrahalsovarden-gallande-kvinnor-som-genomgatt-viktminskningskirurgi-final-002.pdf>

- Vårdprogram levnadsvanor: <https://vardgivare.skane.se/vardriktlinjer/levnadsvanor/>

- Barnöverviksenheten i Region Skåne:

<https://vard.skane.se/skanes-universitetssjukhus-sus/mottagningar-och-avdelningar/barn--och-ungdomsmedicinmottagning-malmo/>

Fetmakirurgi:

- Information inför fetmakirurgi (Kirurgmottagningen Landskrona):

[https://vard.skane.se/lasarettet-i-landskrona/undersokningar-och-behandlingar/fetmaoperation--gastric-bypass/?highlight=information inför fetmakirurgi](https://vard.skane.se/lasarettet-i-landskrona/undersokningar-och-behandlingar/fetmaoperation--gastric-bypass/?highlight=information%20inf%C3%B6r%20fetmakirurgi)

- Komplikationer efter fetmakirurgi (se även vårdprogrammet för vuxna): <https://vardgivare.skane.se/siteassets/1.-vardriktlinjer/regionala-riktlinjer---fillistning/riktlinje-for-komplikationer-efter-fetmakirurgi-2016-10-242.pdf>

- Korrigering av plastikkirurgi efter viktneidgång:

<https://vardgivare.skane.se/siteassets/1.-vardriktlinjer/regionala-wardprogram---fillistning/wardprogram-plastikkirurgi-viktneidgang-2017.pdf>

- Mat vid fetma (SBU 2013): <http://www.sbu.se/sv/publikationer/SBU-utvardear/mat-vid-fetma/>

Referenser Gynekologi

Antikonception

- Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. *Lancet* 1996;347:1713-27)
- Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspert A, Ulmann A, Gainer E. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and metaanalysis. *Lancet* 2010 Feb 13;375(9714):555-62. Epub 2010 Jan 29.
- Kapp N, Curtis K, Nanda K. Progestogen-only contraceptive use among breastfeeding women: a systematic review. *Contraception*. 2010 Jul;82(1):17-37.
- Kapp N, Curtis KM. Combined oral contraceptive use among breastfeeding women: a systematic review. *Contraception*. 2010 Jul;82(1):10-6.
- Trussell J. Contraceptive failure in the United States. *Contraception*. 2011 May;83(5):397-404. Review
- Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2011-9 *BMJ*. 2011 Oct 25;343:d6423. doi: 10.1136/bmj.d6423.
- Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena Fertel Steril. 2012 Mar;97(3):616-22.
- Lidegaard Ø, Milsom I, Geirsson RT, Skjeldestad FE. Hormonal contraception and venous thromboembolism, *Acta Obstet Gynecol Scand*. 2012 Jul;91(7):769-78.
- Läkemedelsverkets behandlingsrekommendation - Antikonception, april 2014, <http://www.lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation---listan/Antikonception/>
- Medical eligibility criteria for contraceptive use, WHO 2015

Endometrios

- https://vardgivare.skane.se/siteassets/1.-vardriktlinjer/regionala-varprogram---fillistning/endometrios---vardprogram-version_2017.pdf

Klimakteriella besvär

- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. *Lancet* 1997;350:1047-1059.
- Weiderpass E; Baron J.A, Adami H-O, Magnusson C m fl Low-potency oestrogen and risk of endometrial cancer: a case control study *Lancet* 199;353:1824-1828.
- Bush TL, Whitman M, Flaws J. Hormone replacement therapy and breast cancer: a qualitative review. *Obstet Gynecol*. 2001 Sept;98(3) 498-508 Review.
- Araujo DAC, Farias MLF, Andrade ATL. Effects of transdermal and oral replacement therapy on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus. *Climacteric* 2002;5:286-92.
- Simunic V, Banovic I, Ciglar S et al. Low dose vaginal estrogen therapy improves urogenital symptoms *Int J Gynecol Obstet* 2003;82:187-97
- Scarabin PY, Oger E, Plu-Bureau G for the Estrogen and thromboembolism risk study group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. *Lancet* 2003 ;362:428-32.
- Manson J , Hsia J, Johnson K et al. Estrogen plus progestins and the risk of coronary heart disease in the WHI. *N Engl J Med* 2003;349:523-34
- Cauley JA, Robbins J et al for the Women's Health Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA* 2003;290(13):1729-38.
- Million Women Study collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. *Lancet* 2003;362:419-27
- Smith NL, Heckbert SR et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. *JAMA* 2004;292:1581-7
- Banks E Beral V, Reeves G, Balkwill A for the Million Women Study Collaborators. Fracture incidence in relation to the pattern of hormone therapy in postmenopausal women. *JAMA* 2004;291:2212-20.
- Margolis KL Bonds DE et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. *Diabetologia* 2004;47(7):1175-87.

- Cushman M, Kuller LH et al for the Women's Health Initiative investigators. Estrogen plus progestogen and risk of venous thrombosis. *JAMA* 2004;292:1573-80
- Mankhey RW, Bhatti F, Marie C. 17-beta-estradiol replacement improves renal function and pathology associated with diabetic nephropathy. *Am J Physiol Renal Physiol* 2004 sep 28.
- Mayes JS, Watson GH. Direct effects of sex steroid hormones on adipose tissue and the metabolic syndrome. *Obes Rev* 2004;4:197-216
- Andersson GL, Limacher M et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004 Apr 14;291(14):1701-12.
- Shumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA* 2004;291:2947-58
- Epstein E, Lindqvist PG, Olsson H. A population-based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden. *Int J Cancer* 2009;125:421-25.
- Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. *Menopause* 2016;23:1199-1203. PubMed

Läkemedel vid graviditet och amning

- Svensk förening för obstetrik och gynekologi. Preeklampsi. ARG-rapport nr 72 Stockholm: SFOG, 2014.

Menorragi

- Svensk förening för obstetrik och gynekologi. Hemostasrubbningar inom obstetrik och gynekologi. ARG-rapport nr 79 Stockholm: SFOG, 2018.
- Läkemedelsverket, Nya åtgärder för att minimera risk för sällsynt men allvarlig leverskada med Esmya mot myom [Internet]. Läkemedelsverket: maj 2018. Tillgänglig från: <https://lakemedelsverket.se/Alla-nyheter/NYHETER--2018/Nya-atgarder-for-att-minimera-risk-for-sallsynt-men-allvarlig-leverskada-med-Esmya-mot-myom/>.

PMS/PMDS

- Freeman EW, Sonheimer SJ. Premenstrual dysphoric disorder: Recognition and treatment. *Prim Care Companion J Clin Psychiatry* 2003;1:30-39
- Mishell DR Jr. Premenstrual disorders: epidemiology and disease burden *Am J Manag care* 2005;16:S473-9
- Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. *Cochrane Review* 2009. DOI: 10.1002/14651858.CD006586.pub3.
- Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. *Cochrane Database Syst Rev*. 2013 Jun 7;6:CD001396. PubMed

Referenser Hjärt- och kärlsjukdomar

Hypertoni

NNT lätt till måttlig hypertoni <http://www.jr2.ox.ac.uk/bandolier/band17/b17-7.html>

Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in uncomplicated hypertension. *Amer J Hypertens* 1998;11:618-29.

Ramipril – njursvikt – ej diabetes

Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with non-nephrotic proteinuria. *Lancet* 1999 Jul 31;354:359-64.

Intensiv terapi – diabetes

Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. *Lancet* 1999 Feb 20;353:617-22.

Äldre med systolisk hypertoni – diabetes resp icke diabetes

Curb JD, Pressel SL, Cutler JA, et al., for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. *JAMA* 1996 Dec 18;276:1886-92.

HOPE

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. *N Engl J Med* 2000 Jan 20;342:145-53.

RENAAL

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Eng J Med* 2001;12:861-869.

IDNT

Renoprotective effect of the angiotensin-receptoragonist irbesartan with nephropathy due to type II diabetes. *N Engl J Med* 2001;345:851- 60.

IRMA-2

The effect of irbesartan on the development of diabetic nephropathy in patients with type II diabetes. *N Eng J Med* 2001;345:870-8.

LIFE

Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359:995–1003.

ALLHAT

Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;288:2981-2997.

ANBP2

A comparison of Outcomes with Angiotensin-converting-Enzyme Inhibitors and Diuretics for Hypertension in the Elderly. The Second Australian National Blood Pressure Study Group (ANBP2). *N Engl J Med* 2003;348:583-592.

SCOPE

The study on cognition and prognosis (SCOPE): principal results of a randomized double-blind intervention trial. *Journal of Hypertension* 2003;21:875-886. SBU rapport nr 170/1, 2004: Måttligt förhöjt blodtryck www.sbu.se

Metaanalys

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. *BMJ* 2004;329:828831.

VALUE

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet* 2004;363:2022-2031.

Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet* 2005;366:1545-53.

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding ben-droflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multi-centre randomised controlled trial. *Lancet* 2008;366:895-906.

ADVANCE

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes (the ADVANCE trial): a randomised controlled trial. *Lancet* 2007;370:829-40.

Nationella riktlinjer för hjärtsjukvård 2008. www.socialstyrelsen.se

ONTARGET

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. The ONTARGET Investigators. *N Engl J Med* 2008;358:1547-59.

TRANSCEND

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The TRANSCEND Investigators. *Lancet* 2008;372:1174-83.

HYVET

Beckett NS et al. The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. *N Engl J Med* 2008

ACCOMPLISH

Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *New Engl J Med* 2008;359:2417-28.

Tandvårds- och läkemedelsförmånsverket. Genomgång av läkemedel mot högt blodtryck 2008. www.tlv.se

SPRINT

Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373(22):2103-16.

HOPE-3

Yusuf S, et al. "Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease". *The New England Journal of Medicine*. 2016. 374(21):2032-2343

Hjärtsvikt**SOLVD**

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *N Engl J Med* 1991 Aug 1;325(5):293-302.

AIRE

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. *Lancet* 1993 Oct 2;342(8875):821-8.

CIBIS II

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999 Jan 2;353 (9146):9-13.

MERIT HF

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Hallinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *JAMA* 2000 Mar 8;283(10):1295-302.

COPERNICUS

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacci P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001 May 31;344(22):1651-8.

RALES

Pitt B, Zannad F, Remme, WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999 Sep 2;341(10):709-17.

DIG

The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. *N Engl J Med* 1997 Feb 20;336(8):525-33.

CHARM

Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. *Lancet* 2003;362:772-76

McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. *Lancet* 2003;362:767-71

Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved Trial. *Lancet* 2003;362:777-81.

Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. *Lancet* 2003;362:759-66

Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;349:1893-1906.

EPHESUS

Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. *N Engl J Med* 2003;348:1309-21.

EMPHASIS-HF

Zannad F, et al. "Eplerenone in patients with systolic heart failure and mild symptoms". *The New England Journal of Medicine*. 2011. 364(1):11-21.

CONFIRM-HF

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet, Georg Ertl, Michel Komajda, Viacheslav Mareev, Theresa McDonagh, Alexander Parkhomenko, Luigi Tavazzi, Victoria Levesque, Claudio Mori, Bernard Roubert, Gerasimos Filippatos, Frank Ruschitzka, Stefan D. Anker, *European Heart Journal* Aug 2014, DOI: 10.1093/eurheartj/ehu385

PARADIGM-HF

John J.V., McMurray, M.D., Milton Packer, M.D., Akshay S. Desai, M.D., M.P.H., Jianjian Gong, Ph.D., Martin P. Lefkowitz, M.D., Adel R. Rizkala, Pharm.D., Jean L. Rouleau, M.D., Victor C. Shi, M.D., Scott D. Solomon, M.D., Karl Swedberg, M.D., Ph.D., and Michael R. Zile, M.D. for the PARADIGM-HF Investigators and Committees. *N Engl J Med* 2014;371:993-1004 September 11, 2014 DOI:10.1056/NEJMoa1409077

Antikoagulantia och trombocythämmare**ISIS-2**

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. *Lancet* 1988 Aug 13;2(8607):349-60.

RISC

Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. *Lancet* 1990 Oct 6;336(8719):827-30.

Juul Möller

Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. *Lancet* 1992 Dec 12;340(8833):1421-5.

CURE

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001 Aug 16;345(7):494-502.

Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events (CHARISMA). *N Engl J Med* 2006;354.

Nationella riktlinjer för hjärtsjukvård 2008. www.socialstyrelsen.se

ACTIVE

The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation *N Engl J Med* 2009;360:2066-2078. Triton-TIMI 38

Wiviott SD et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. *N Engl J Med* 2007;357:2001-15.

PLATO

Wallentin L, Harrington R et al, Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes, *N Engl J Med* 2009;361:1045-1057

PEGASUS

Bonaca, M.P., et al., Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. *New England Journal of Medicine*, 2015. 372(19): p. 1791-1800

RE-LY

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139-1151

ROCKET AF

Patel MR, Mahaffey KW, Garg J, et al Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011 Sep 8;365(10):883-91

ARISTOTLE

Granger CB, Alexander JH, McMurray JJV, et al Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011 Sep 15;365(11):981-92

ENGAGE AF-TIMI 48

Guigliano RP, et al. "Edoxaban versus warfarin in patients with atrial fibrillation". *The New England Journal of Medicine*. 2013. 369(22):2093-104.

Barclay, L., Recommendations for Treating Peptic Ulcer Disease Reviewed. *American Family Physician*, 2007;76:1005-1012

Miller, T.A., Modern surgical care physiologic foundations and clinical applications, 2006;1:356-357

Gilard, M., et al., Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. *J Thromb Haemost*, 2006;4(11):2508-9

Gilard, M., et al., Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. *J Am Coll Cardiol*, 2008;51(3):256-60

Frere, C., et al., Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. *Am J Cardiol*, 2008;101(8):1088-93

Aubert, R.E., et al., Abstract 3998: Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study. *Circulation*, 2008;101(8):1088-93

Ho, P.M., et al., Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Pro- ton Pump Inhibitors Following Acute Coronary Syndrome. *JAMA* 2008;101(8):1088-93

O'Donoghue, M.L., et al., Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. *Lancet* 2009;374(694):989-97

Ho, P.M., et al., Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. *JAMA* 2008;299(5):532-9

FDA, Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix). 2009. IRF, Ringe klinisk betydning af interaktion mellem PPI og clopidogrel. 2009.

Referenser Hud

Aktinisk keratos

1. de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. *Br J Dermatol.* 2007;156:222-230. Erratum in: *Br J Dermatol.* 2008;158:873.
2. Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth, Nast A. The natural history of actinic keratosis: a systematic review. *Br J Dermatol.* 2013;169:502-18
3. Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. *Br J Dermatol.* 2009;161:78-84
4. Werner RN et al. Evidence-and consensus-based (S3) Guidelines for the treatment of Actinic Keratosis-International League of Dermatological Societies in cooperation with the European Dermatology Forum. *J Eur Acad Dermatol Venereol* 2015; 29; 2096-2079.
5. Gupta AK et al. Interventions for actinic keratosis. *Cochrane Database Syst Rev.* 2012; 12; CD004415, Epub Dec 201
6. Gupta AK et al. Network meta-analysis for the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. *Br J Dermatol* 2013; 169: 250-259
7. Stockfleth et al: New topical treatment options for actinic keratosis: a systematic review. *Acta Derm Venereol* 2016; 96: 17-22
8. Lebwohl M et al. Ingenol mebutate gel for actinic keratosis. *N Engl J Med* 2012; 366
9. Wiegell SR et al. Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. *J Eur Acad Dermatol Venereol* 2012; 26: 673-679

Akne

10. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden J, et al. Management of acne: a report from a global alliance to improve outcomes in acne. *J Am Acad Dermatol.* 2003;49(1 Suppl):S1-37.
11. Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden J, et al. New insights into the management of acne: an update from the global alliance to improve outcomes in acne group. *J Am Acad Dermatol.* 2009;60(Suppl):S1-50
12. Chernyshov PV, Tomas-Aragones L, Manolache L, Svensson A, Marron SE, Evers AWM, Bettoli V, Jemec GB, Szepietowski JC. Which acne treatment has the best influence on health-related quality of life? Literature review by the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. *J Eur Acad Dermatol Venereol* 2018;32:1410-1419.
13. Fiedler F, Stangl GI, Fiedler E, Taube KM. Acne and Nutrition: A systematic review. *Acta Derm Venereol* 2017;97:7-9.
14. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. *Lancet* 2012;379:361-372.
15. Behandling av akne - behandlingsrekommendation. Information från Läke-medelsverket , 2014; 4: 15-24
16. Koo EB, Petersen TD, Kimball AB. Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. *J Am Acad Dermatol* 2014;71:450-459.

Rosacea

17. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MMD, Charland L. Interventions for rosacea. *Cochrane Database Syst Rev,* 2015.
18. Moore A, Kempers S, Murakawa G et al: Long-term safety and efficacy of once-daily topical brimonidin tartrate gel 0,5% for the treatment of moderate to severe facial erythema of rosacea: result of a 1-year open-label study *J Drugs Dermatol* 2014;13:56-61

Perioral dermatit

19. Tempark T, Shwayder T. Perioral dermatitis: A review of the condition with special attention to treatment options. *Am J Clin Dermatol* 2014;15:101-113

Atopisk dermatit

20. Williams H. Established corticosteroid creams should be applied only once daily in patients with atopic eczema. *BMJ* 2007;334:1272-1273.
21. Behandling av atopiskt eksem. Behandlingsrekommendation. Information från Läke-medelsverket 2005; 2: 1-12.
22. Svedman C, Svensson Å. Atopisk dermatit – utredning och behandling *Allergi i Prakxis* 2016;1:6-13.
23. Schmitt J, von Kobyletzki L, Svensson Å, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin-inhibitors for atopic eczema: systematic review and meta-analysis of randomised controlled trials. *Br J Dermatol* 2011;164:415-428
24. Francis NA, Ridd MJ, Thomas-Jones E, Shepherd V, Butler CC, Hood K, et al. A randomized placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the children with eczema, Antibiotic Management (CREAM) study. *Health Technol Assess* 2016;20:1-84.

25. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce *Staphylococcus aureus* in the management of atopic eczema: an updated Cochrane review. *Br J Dermatol.* 2010;163:12-26.
26. Wollenberg A, Oranje A, Deleuran M, Simon D et al. ETFAD/EADV Eczema Task Force 2015 position paper on diagnosis and treatment of atopic dermatitis. *J Eur Acad Dermatol Venereol* 2016 30: 729-47.
27. Proudfoot L., Powell A., Avis S, Barbarot S, Svensson Å et al. The European treatment of severe atopic eczema in children taskforce (TREAT) survey. *Br J Dermatol* 2013;169:901-909.
28. Simon D, Bieber T. Systemic therapy for atopic dermatitis. *Allergy* 2014;69:46-55. *Dermatology.* 2017;233:344-357.
29. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet* 2017;389:2287-2303.
30. Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. *J Am Acad Dermatol* 2017; 77:623-633.
31. Garritsen FM, van den Heuvel JM, Bruijnzeel-Koomen CAFM, Maitland-van der Zee AH, van den Broek MPH, de Bruin-Weller MS. Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands. *J Eur Acad Dermatol Venereol* 2018 [Epub ahead of print]

Handeksem

32. Lindberg. M. Meding B. Stenberg B. Svensson Å. Handeksem är en folksjukdom som påverkar livskvalitet och arbetsförmåga. *Läkartidningen* 2013;110:23-29.
33. Kadyk DL, McCarter K, Achen F, Belsito DV. Quality of life in patients with allergic contact dermatitis. *J Am Acad Dermatol* 2003;49:1037- 48.
34. National Klinisk retningslinje för behandling af handeksem Sundhedsstyrelsen, Danmark 2016-10-04
35. Regionala riktlinjer för behandling med licenspreparatet alitretinoin (Toctino®) vid svårt handeksem i Region Skåne <http://vardgivare.skane.se/varrdiktlinjer/lakemedel/>

Seborroiskt eksem

36. Hay RJ, Malassezia, dandruff and seborrhoeic dermatitis: an overview.. *Br J Dermatol.* 2011;165: Suppl 2:2-8.
37. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis (Review). *The Cochrane Library* 2015, Issue 5.
38. Naldi L, Diphooorn J. Seborrhoeic dermatitis of the scalp. *BMJ Clin Evid.* 2015;1713.
39. Stefanaki I, Katsambas A. Therapeutic update on seborrheic dermatitis. *Skin Therapy Lett.* 2010; 15:1-4.

Mjukgörande medel vid torr hud

40. Grimalt R, Mengeaud V, Cambazard F, The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. *Dermatology* 2007;214:61-7.
41. Lodén M, Wirén K, Smerud K, Meland N, Hønnås H, Mørk G, Lützw-Holm C, Funk J, Meding B. Treatment with a barrier-strengthening moisturizer prevents relapse of hand-eczema. An open, randomized, prospective, parallel group study. *Acta Derm Venereol.* 2010;90:602- 606.
42. van Zuuren EJ, Fedorowicz Z, Christensen, R, Lavrijsen APM, Arents BWM. Emollients and moisturisers for eczema. *Cochrane Database of Systematic Reviews* 2017, Issue 2. Art No.: CD012119. DOI: 10.1002/14651858.CD012119.pub2.
43. Norrlid H, Hjalte F, Lundqvist A, Svensson A and Ragnarson Tennvall G. Cost-effectiveness of maintenance treatment with a barrier-strengthening moisturizing cream in patients with atopic dermatitis in Finland, Norway and Sweden. *Acta Derm Venereol* 2016; 96; 173-176
44. Faergemann J, Olsson P, Svensson Å. A randomized, single-blind comparison of the efficacy, tolerability and cosmetic acceptance of propyl or fenuril treatment of patients with dry skin. *Acta Derm Venereol.* 2009; 89: 305-7.

Psoriasis

45. Mason AR, Mason J, Cork M, Dooley G, Hancock H, Topical treatment for chronic plaque psoriasis. *Cochrane Database of Systematic reviews* 2013, Issue 3, Art No: CD005028. DOI: 10.1002/14651858. CD005028.pub 3.
46. Naldi L, Svensson A, Zenoni D, Diepgen T, Elsner P, Grob JJ, Coenraads PJ, Bouwes Bavinck JN, Maccagni A, Linder D, Williams H; on behalf of the European Dermato-Epidemiology Network (EDEN). Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis. Update of the EDEN Psoriasis Survey 2001-2006. *Br J Dermatol.* 2010;162:384-9.
47. Ljusbehandling och systemisk behandling av psoriasis 2018. SBU rapport 278 <https://www.sbu.se/278>
48. Rodríguez-Zúñiga MJM, Garcia-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic

syndrome. *J AM Acad Dermatol.* 2017;77: 657-666

49. Läkemedelsverket 2011. Läkemedelsbehandling av psoriasis – ny rekommendation. Information från Läkemedelsverket 4:2011:1-24.
50. Nationella riktlinjer för vård vid psoriasis. Socialstyrelsen 2018. <https://www.socialstyrelsen.se/riktlinjer/nationellriktlinjer/psoriasis>
51. Queille-Roussel C, Hoffmann V, Ganslandt C, Krog Hansen K. Comparison of the Antipsoriatic Effect and Tolerability of Calcipotriol-Containing Products in the Treatment of Psoriasis Vulgaris Using a Modified Psoriasis Plaque Test. *Clin Drug Investig* 2012; 32: 613-619
52. Sticherling M1, Eicke C, Anger T. Practicability of combined treatment with calcipotriol/betamethasone gel (Daivobet® Gel) and improvement of quality of life in patients with psoriasis. *J Dtsch Dermatol Ges.* 2013;11:420-27.
53. Koo J, Tying S, Werschler WP, Bruce S et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study. *J Dermatolog Treat.* 2016; 27: 120-7
54. Paul C, Leonardi C, Menter A, et al Calcipotriol plus betamethasone dipropionate aerosol foam in patients with moderate-to-severe psoriasis: Sub- group analysis of the PSO-ABLE study. *Am J Clin Dermatol;* 2017.18:405-411
55. Mrowietz U, de Jong E, Kragballe K, Langley R et al A consensus report on appropriate treatment optimization and transitioning in the management of moderate to severe plaque psoriasis *J Eur Acad Dermatol Venereol* 2013.
56. Nast A, Gisondi P, Ormerod AD et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015 *J Eur Acad Dermatol Venereol.* 2015;12:2277-94.
57. Svenska Sällskapet för Dermatologi och Venereologis behandlingsrekommendationer för systemisk behandling av psoriasis

Kronisk urtikaria

58. Zuberbier T et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. *Allergy* 2018;73:1393-1414.
59. Wallengren J. Urtikaria och angioödem. I *Allergi och Astma.* E Hedlin G och Larsson K. 2009. 381-398. Studentlitteratur
60. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. *J Allergy Clin Immunol* 2012; 129: 1307-1313.
61. Krause K et al. How not to miss autoinflammatory diseases masquerading as urticaria. *Allergy.* 2012;67:1465-74.

Kronisk klåda

62. European guideline on chronic pruritus. Weisshaar E, Szepietowski JC, Darsow U, Misery L, Wallengren J, Mettang T, Gieler U, Lotti T, Lambert J, Maisel P, Streit M, Greaves MW, Carmichael AJ, Tschachler E, Ring J, Ständer S. *Acta Derm Venereol.* 2012;92:563-581.
63. Drug-induced pruritus: a review. Reich A, Ständer S, Szepietowski JC. *Acta Derm Venereol.* 2009;89:236-244
64. Clinical practice. Chronic pruritus. Yosipovitch G, Bernhard JD. *N Engl J Med.* 2013;368:1625-34.
65. Legat FJ. Importance of phototherapy in the treatment of chronic pruritus. *Hautarzt.* 2018 [Epub ahead of print]
66. Systemic therapy for atopic dermatitis. Simon D, Bieber T. *Allergy.* 2014;69:46-55.
67. Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. Spring P, Gschwind I, Gilliet M. *Clin Exp Dermatol.* 2014 ;39:468-73.
68. Azathioprine treatment of intractable pruritus: A retrospective review. Maley A, Swerlick RA. *J Am Acad Dermatol.* 2015;73:439-43.
69. Fernandez JM, Fernandez AP, Lang DM. Biologic Therapy in the Treatment of Chronic Skin Disorders. *Immunol Allergy Clin North Am.* 2017;37:315-327.
70. Zeidler C, Tsianakas A, Pereira M, Ständer H, Yosipovitch G, Ständer S. Chronic prurigo of nodular type: A review *Acta Derm Venereol* 2018;98;173-179.

Impetigo

71. Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC, Berger M, van der Wouden JC Interventions for impetigo. *Cochrane Database Syst Rev.* 2012;1:CD003261. Review.
72. Hud- och mjukdelsinfektion. Läkemedelsverket 2018. <https://lakemedelsverket.se/hud-mjukdelsinfektion>
73. McNeil JC, Hulten KG, Kaplan SL, Mason EO. Decreased susceptibilities to retapamulin, mupirocin and chlorhexidine among *Staphylococcus aureus* isolates causing skin and soft tissue infections in otherwise healthy children. *Antimicrob Agents Chemother.* 2014;58:2878-83

Klamydiainfektion

74. Low N, Egger M, Sterne JA, Harbord RM, Ibrahim F, Lindblom B, Herrmann B. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women's Cohort Study. *Sex Transm Infect.* 2006;82:212-8
75. Kumamoto Y, Matsumoto T, Fujisawa M, Arakawa S. Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in urogenital and

oral specimens using the cobas® 4800, APTIMA Combo 2® TMA, and ProbeTec™ ET SDA assays. *Eur J Microbiol Immunol* (Bp). 2012;2:121-7.

76. Sexuellt överförbara bakteriella infektioner - behandlingsrekommendation: Information från Läkemedelsverket 2015;26.
77. Svenska sällskapet för dermatologi och venereologi (SSDV:s) rekommendationer för behandling av sexuellt överförbara infektioner (STI) uppdaterad, version 4, 2017.

Skabb

78. Strong M, Johnstone P. Interventions for treating scabies. *Cochrane Database of Systematic Reviews* 2007, Issue 3.

Mykoser

79. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. *Cochrane Database of Systematic Reviews* 2007, Issue 3.
80. Chang CH, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a metaanalysis. *Am J Med* 2007; 120:791-8.
81. Behandling av dermatomykoser - Behandlingsrekommendation. Info från Läkemedelsverket 2004; 6:10-18.
82. Panthagani AP, Tidman MJ. Diagnosis directs treatment in fungal infections of the skin *Practitioner* 2015;259:25-29 .
83. Nurbhai M, Grimshaw J, Watson M, Bond CM, Mollison JA, Ludbrook A. Oral versus intra-vaginal imidazole and triazole antifungal treatment of uncomplicated vulvovaginal candidiasis (thrush). *Cochrane Database of Systematic Reviews* 2007, Issue 4.

Hidradenit

84. Gregor B E Jemec. Hidradenitis suppurativa. *The New England Journal of Medicine* 2012; 366:158-64.
85. Hessel H Van der Zee. Hidradenitis Suppurativa: Viewpoint of clinical phenotyping, pathogenesis and novel treatments. *Experimental Dermatology* 2012 ; 21: 735-39.
86. European Dermatology Forum S1 guideline 2014 <http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous>
87. Lynette J. Margesson et al. Hidradenitis suppurativa. *Best Practise & Research Clinical Obstetrics and Gynaecology* 2014;28:1013-1027
88. Maiwand Nazary et al. Pathogenesis and pharmacotherapy of Hidradenitis Suppurativa. *European Journal of Pharmacology* 2011;762:1-8
89. Charles B. Kromann et al. The Influence of Body Weight on the Prevalence and Severity of Hidradenitis Suppurativa. *Acta Derm Venereol* 2014; 94: 553-7.
90. Deirdre Nathalie Dufour et al. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. *Postgrad Med J* 2014;90:216-21.
91. Zouboulis CC, editor. Diagnostic criteria for Hidradenitis suppurativa. Second international Hidradenitis suppurativa research symposium; 2009. San Fransisco.
92. Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. *J Am Acad Dermatol.* 2015;73(Suppl 1):S82-88.
93. Jemec GB, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. *J Am Acad Dermatol.* 2015;73(Suppl 1):S4-7.

Referenser Infektionssjukdomar

Infektion

1. Leibovitz E, Greenberg D, Piglansky L, Raiz S, Porat N, Press J, et al. Recurrent acute otitis media occurring within one month from completion of antibiotic therapy: relationship to the original pathogen. *Pediatr Infect Dis J*. 2003 Mar;22(3):209-16.
2. van Dongen TM, van der Heijden GJ, Venekamp RP, Rovers MM, Schilder AG. A trial of treatment for acute otorrhea in children with tympanostomy tubes. *N Engl J Med* 2014 Feb 20;370(8):723-33.
3. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Fokkens WJ, Lund VJ, Mullol J, Bachert C et al. *Rhinology* 50 suppl 23 March 2012
4. Behandling av bakteriella hud-och mjukdelsinfektioner i öppenvård - behandlingsrekommendationer. Information från Läkemedelsverket. 2018:3

Referenser Kognitiva sjukdomar

- Atri A, Shaughnessy LW et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. *Alzheimer Dis Assoc Disord* 2008;22: 209-21.
- Ballard CG, Waite J et al. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. *Cochrane Database Syst Rev* 2006, Issue 1. Art. No: CD003476. DOI: 10.1002/14651858.CD003476.pub2.
- Health Quality Ontario 2013. Vitamin B and cognitive function: an evidence-based analysis. *Ont Health Technol Assess Ser*. 2013 Nov 1;13(23):1-45.
- Howard R, McShane R et al. Donepezil and memantine for moderate-to-severe Alzheimer's Disease, *NEJM*, 2012; 366: 893-903. DOI: 10.1056/NEJMoa1106668
- Kognitiv medicin. Lars-Olof Wahlund, Christer Nilsson, Anders Wallin (red.) Norstedt 2011
- Lopez OL, Becker JT et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. *J Neurol Neurosurg Psychiatry* 2009; 80: 600-7.
- Läkemedelsverket. Behandling och bemötande vid Beteendemässiga och Psykiska Symtom vid Demenssjukdom – "BPSD". Information från läkemedelsverket 5: 2008. www.lakemedelsverket.se
- NICE 2011. Donepezil, galantamine, rivastagmine and memantine for the treatment of Alzheimer's disease. NICE technology appraisal guidance 217.
- Region Skåne 2015. Vårdprogram för sjukdomar med varaktig kognitiv svikt. <http://vardgivare.skane.se/vardriktlinjer/medicinska-omraden/kognitiva-sjukdomar-och-demens/>
- SBU Statens beredning för medicinsk utvärdering. 2006. Demenssjukdomar. Rapportnr 172.
- Smith AD; Refsum H, Bottiglieri T, Fenech M, Hooshmand B, McCaddon A, Miller JW, Rosenberg IH, Obeid R. "Homocysteine and Dementia: An International Consensus Statement", *J Alheimers Dis*, 2018; 62(2):561-570.
- Socialstyrelsen. 2010. Nationella riktlinjer för vård och omsorg vid demenssjukdom. Art. No 2010-5-1.
- Socialstyrelsen. 2017. Indikatorer för god läkemedelsterapi hos äldre. Art. No. 2017-6-7. www.socialstyrelsen.se
- Vägverkets författningssamling, VVFS 2008:166. Vägverkets föreskrifter om ändring i föreskrifterna (VVFS 2008:158) om medicinska krav för innehav av körkort mm, 10:e kapitlet demens och andra kognitiva störningar

Referenser Lipidrubbing

1. Socialstyrelsen. Nationella riktlinjer för hjärtsjukvården. 2008, kompletterade 2011. <http://www.socialstyrelsen.se/nationellriktlinjerforhartsjukvard/>
2. Socialstyrelsen. Nationella riktlinjer för strokesjukvård. 2009, kompletterade 2011. <http://www.socialstyrelsen.se/nationellriktlinjerforstrokesjukvard>
3. Socialstyrelsen. Nationella riktlinjer för diabetesvården. 2010. <http://www.socialstyrelsen.se/nationellriktlinjerfordiabetesvarden>.
4. Läke medelsverket. Förebyggande av aterosklerotisk hjärt-kärlsjukdom. 2006;3(17).
5. Reiner Z, Catapano AL, De Backer G et al. ESC/EASEuropean Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 2011 Jul;32(14):1769-818. <http://www.escardio.org/guidelines>
6. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J*. 2012 Jul;33(13):1635-701. <http://www.escardio.org/guidelines>
7. Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: A randomised controlled trial. *Lancet* 2011; 387:2013-20.
8. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. *Cerebrovasc Dis* 2007;24(2-3):170-82.
9. Collins R, Armitage J, Parish S et al (HPS). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. *Lancet* 2004 Mar 6;363(9411):757-67.
10. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012 Aug 11;380(9841):581-90.
11. Taylor F, Ward K, Moore THM, et al. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2011; 1 (CD004816).
12. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008 Jan 12;371(9607):117-25.
13. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet* 2010; 375:1875-84.
14. Ray KK, Seshasai SR, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. *Arch Intern Med* 2010;170(12):1024-31.
15. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ*. 2009;338:b2376. doi:10.1136/bmj.b2376.
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering in 20 536 high-risk individuals: a randomized placebocontrolled trial. *Lancet* 2002;360:7-22.
17. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170 000 participants in 26 randomised trials. *Lancet* 2010; 376: 1670–81.
18. Armitage J, Bowman L, Wallendszus K et al (SEARCH). Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet* 2010 Nov 13;376(9753):1658-69.
19. Emberson J, Bennett D, Link E et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study *Lancet* 2011 Feb 5;377(9764):469-76.
20. Afilalo J, Duque G, Steele R et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. *J Am Cardiol* 2008;51(1):37-45.
21. Ridker PM, Danielson E, Fonseca FA et al (JUPITER). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;359(21):2195-207.

22. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;350:1495-504.
23. Di Sciascio G, Patti G, Pasceri V et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. *J Am Coll Cardiol* 2009;54:558-65.
24. Patti G, Cannon CP, Murphy SA et al. Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention/ Clinical Perspective: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies. *Circulation* 2011;123:1622-1632.
25. Kastelein JJ, Akdim F, Stroes ES et al (ENHANCE). Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N Engl J Med* 2008;358(14):1431-43.
26. Rossebø AB, Pedersen TR, Boman K et al (SEAS). Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med* 2008;359(13):1343-56.
27. Baigent C, Landray MJ, Reith C et al (SHARP). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet* 2011 Jun 25;377(9784):2181-92.
28. Boden WE, Probstfield JL, Anderson T et al (AIM-HIGH). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med* 2011 Dec 15;365(24):2255-67.
29. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statins trials. *Lancet* 2010; 375:735-42.
30. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. A Meta-analysis. *JAMA* 2011;305:2556-64.
31. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M et al. Metaanalysis of drug-induced adverse events associated with intensive-dose statin therapy. *Clin Therapy* 2007 Feb;29(2):253-60.
32. Kjekshus J, Apetrei E, Barrios V et al (CORONA). Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007;357(22):2248-61.
33. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. *Am J Cardiol* 2006;97(8A):77C-81C.
34. Amarenco P, Bogousslavsky J, Callahan A et al (SPARCL). High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;355(6):549-59.
35. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. *Int J Cancer* 2007;120(4):833-43.
36. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. *JAMA* 2006;295(1):74-80.
37. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomized placebo-controlled trial. *BMC Med* 2005;3:6.
38. Christopher P. Cannon, M.D., Michael A. Blazing, M.D., Robert P. Giugliano, M.D et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med* 2015; 372:2387-2397.
39. Att förebygga aterosklerotisk hjärt-kärlsjukdom med läkemedel – behandlingsrekommendation Information från Läkemedelsverket 2014: (25) 5
40. HOPE-3 Yusuf S, et al. "Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease". *The New England Journal of Medicine*. 2016. 374(21):2032-2343
41. Sabatine MS, Giugliano RP, Keech AC, et al;FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. Epub 17 mar 2017. doi: 10.1056/NEJMoa1615664.

Referenser Matsmältningsorgan

Dyspepsi:

Bakgrund:

Nationell riktlinje 2016: Outredd dyspepsi, okomplicerade duodenal- och ventrikelsår samt funktionell dyspepsi. Publicerat under riktlinjer på Svensk Gastroenterologisk Förenings hemsida

http://svenskgastroenterologi.se/wp-content/uploads/2017/06/outredd_dyspepsi_h_pylori_ulkus_161118-1.pdf

Standardiserat vårdförlopp för matstrups- och magsäckscancer

<http://www.cancercentrum.se/syd/cancerdiagnoser/matstrupe-och-magsack/vardforlopp/>

Kortversion för primärvården (AKO-riktlinjer)

<http://vardgivare.skane.se/vardriktlinjer/medicinska-omraden/cancer/ako/matstrups--och-magsackscancer/>

Helicobacter pylori (Hp)

Dyspepsi och reflux, en systematisk litteraturöversikt, SBU-rapport 2007

Nationell riktlinje 2016: Outredd dyspepsi, okomplicerade duodenal- och ventrikelsår samt funktionell dyspepsi. Publicerat under riktlinjer på Svensk Gastroenterologisk Förenings hemsida

http://svenskgastroenterologi.se/wp-content/uploads/2017/06/outredd_dyspepsi_h_pylori_ulkus_161118-1.pdf

NSAID-orsakad ulcussjukdom

Blödande magsår, en systematisk litteraturöversikt, SBU-rapport maj 2011

Coxib and Traditional NSAID Trialists' Collaboration. The Lancet ;Early Online Publication, 30 May 2013, Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Dyspepsi-preparatval

Läkemedelsverkets produktmonografi av Nexium (esomeprazol) (Tryckt version: 2000;11). <http://www.lakemedelsverket.se/malgrupp//Halso--sjukvard/Monografier-varderingar/Monografier-Humanlakemedel/Humanlakemedel-Arkiv/Nexium-esomeprazol/>

Nationell riktlinje 2016: Outredd dyspepsi, okomplicerade duodenal- och ventrikelsår samt funktionell dyspepsi. Publicerat under riktlinjer på Svensk Gastroenterologisk Förenings hemsida

http://svenskgastroenterologi.se/wp-content/uploads/2017/06/outredd_dyspepsi_h_pylori_ulkus_161118-1.pdf

STW5 (Iberogast)-a safe and effective standard in the treatment of functional gastrointestinal disorders.

Ottlinger B, Storr M, Malfetheiner P, Allescher AD. Wien Med Wochenschr. 2013 Feb;163(3-4):65-72.

Utsättning av PPI

Backman L, Schmidt D, Vitols S. Protonpumpshämmare misstänks ge allvarliga biverkningar. Försiktigare förskrivning bör övervägas och på korrekta indikationer. Läkartidningen nr 16 2013; 110, 828-31.

Lundgren C. Protonpumpshämmare A02BC. FAS UT 3, s 26-33.

Utredning av patienter med ändrade avföringsvanor

Standardiserat vårdförlopp för tjocktarms- och ändtarmscancer

<https://www.cancercentrum.se/samverkan/cancerdiagnoser/tjocktarm-andtarm-och-anal/tjock--och-andtarm/vardprogram/>

Kortversion för primärvården (AKO-riktlinjer)

<http://vardgivare.skane.se/vardriktlinjer/medicinska-omraden/cancer/ako/tjock--och-andtarmscancer/>

Irritabel Bowel Syndrome (IBS)

Rom IV kriterier:

Lacy et al. Gastroenterology 2016,150:1393-1407.

Läkemedelsboken

IBS-guidelines Svensk Gastroenterologisk Förening (SGF)

Sammanfattning:

http://svenskgastronterologi.se/wp-content/uploads/2017/06/riktlinjer_ibs-1.pdf

Bakgrundsdokumentation: http://svenskgastronterologi.se/wp-content/uploads/2017/06/bakgrundsdokument_ibs-1.pdf

A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome. Chao GQ, Zhang S. Intern Med 2013;52(4):419-24.

Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Bundeff AW, Woodis CB. Ann Pharmacother 2014 Jun;48(6):77-84.

STW5 (lberogast)-a safe and effective standard in the treatment of functional gastrointestinal disorders.

Ottillinger B, Storr M, Malfetheiner P, Allescher AD. Wien Med Wochenschr. 2013 Feb;163(3-4):65-72.

EPAR Truberzi (sammanfattning)

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004098/WC500213371.pdf

Truberzi – TLV-beslut:

https://www.tlv.se/Upload/Beslut_2017/bes170420_truberzi.pdf

Eluxadolin (Truberzi): Risk för pankreatit och spasm i Oddis sfinkter

[https://docetp.mpa.se/LMF/Truberzi%20\(eluxadolin\)%202017-11-03%20DHPC.pdf](https://docetp.mpa.se/LMF/Truberzi%20(eluxadolin)%202017-11-03%20DHPC.pdf)

Mikroskopisk kolit

Medicinska mag- och tarmsjukdomar. Henry Nyhlin (red), Studentlitteratur 2008; 351-8.

Divertikulos och divertikulit

Gastroenterologi och hepatologi av Rolf Hultcrantz mfl (2011), kapitel 28.

Internetmedicin.se , avsnitt om divertikulit:

<http://www.internetmedicin.se/page.aspx?id=1477>

Exokrin pankreasinsufficiens:

Internetmedicin, avsnitt om Exokrin pancreasinsufficiens (EPI):

<http://www.internetmedicin.se/page.aspx?id=5927>

Löhr et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017 Mar;5(2):153-199

Anemi**Järnbristanemi**

Anemia in Inflammatory Bowel Diseases. Christoph Gasche (red), UNI-MED Verlag AG 2008; 37-53

<http://www.lakemedelsverket.se/Alla-nyheter/Nyheter-2013/Nya-rekommendationer-for-att-hantera-risken-for-allergiska-reaktioner-av-intravenosa-jarnpreparat/>

Referenser Munhålan

Medel mot karies

- Ekstrand KR1, Poulsen JE, Hede B, Twetman S, Qvist V, Ellwood RP. A randomized clinical trial of the anti-caries efficacy of 5,000 compared to 1,450 ppm fluoridated toothpaste on root caries lesions in elderly disabled nursing home residents. *Caries Res.* 2013;47(5):391-8.
- Fure S, Gahnberg L, Birkhed D. A comparison of four home-care fluoride programs on the caries incidence in the elderly. *Gerodontology.* 1998;15:51-60
- Griffin SO, Regnier E, Griffin PM, Huntley V. Effectiveness of fluoride in preventing caries in adults. *J Dent Res.* 2007;86:410-415.
- Marinho VCC, Higgins JPT, Logan S, Sheiham A. Fluoride toothpastes for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews* 2003, Issue 1. Art. No.: CD002278. DOI: 10.1002/14651858.CD002278.
- Marinho VCC, Higgins JPT, Logan S, Sheiham A. Fluoride mouthrinses for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews* 2003, Issue 3. Art. No.: CD002284. DOI: 10.1002/14651858.CD002284
- Marinho VCC, Higgins JPT, Logan S, Sheiham A. Fluoride gels for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews* 2002, Issue 1. Art. No.: CD002280. DOI: 10.1002/14651858.CD002280.
- Marinho VCC, Higgins JPT, Logan S, Sheiham A. Fluoride varnishes for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews* 2002, Issue 1. Art. No.: CD002279. DOI: 10.1002/14651858.CD002279.
- Moberg Sköld U, Birkhed D, Borg E, Petersson LG. Approximal caries development in adolescents with low to moderate caries risk after different 3-year school-based supervised fluoride mouth rinsing programmes. *Caries Res.* 2005;39:529-535.
- Nordström A1, Birkhed D. Preventive effect of high-fluoride dentifrice (5,000 ppm) in caries-active adolescents: a 2-year clinical trial. *Caries Res.* 2010;44(3):323-31.
- SBU. Prevention of Dental Caries. A Systematic review. The Swedish Council on Technology Assessment in Health Care SBU report No161 In Swedish. 2002.
- SBU. Caries Diagnosis, Risk Assessment and Non-operative Treatment of Early Caries Lesions. The Swedish Council on Technology Assessment in Health Care SBU report No 188 In Swedish. 2007.
- Socialstyrelsen. National Guidelines for Adult Dental Care 2011. www.socialstyrelsen.se/nationalguidelines (21 november 2016)
- Walsh T, Worthington HV, Glenny AM, Appelbe P, Marinho VCC, Shi X. Fluoride toothpastes of different concentration for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD007868. DOI: 10.1002/14651858.CD007868.pub2.
- Wyatt CCL, MacEntee MI. Caries management for institutionalized elders using fluoride and chlorhexidine mouthrinses. *Community Dent Oral Epidemiol.* 2004;32:322-328.

Medel för salivstimulering

- LeVeque FG, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. *J Clin Oncol.* 1993;11:1124-1131.
- Vivino FB, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. *Arch Intern Med.* 1999;159:174-81.

Antiseptiska medel för lokal behandling

- SBU. Chronic periodontitis – prevention, diagnosis and treatment. Stockholm: Swedish Council on Health Technology Assessment in Health Care (SBU); 2004. SBU report no 169 (in Swedish).

Medel för lokal behandling av munslemhinneförändringar

- Al-Hashimi et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2007;103 Suppl:S25.e1-12.
- Carbone M, Arduino PG, Carrozzo M, Caiazzo G, Broccoletti R, Conrotto D, Bezzo C, Gandolfo S. Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. *Oral Pathol Med.* 2009 Feb;38(2):227-33
- Fridh G, Koch G. Effect of a mouth rinse containing amyloglucosidase and glucose oxidase on recurrent aphthous ulcers in children and adolescents. *Swed Dent J.* 1999;23(2-3):49-57
- González-García A, Diniz-Freitas M, Gándara-Vila P, Blanco-Carrión A, García-García A, Gándara-Rey J. Triamcinolone acetate mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over-infection. *Oral Dis.* 2006 Nov;12(6):559-65.
- Henricsson V, Axéll T. Treatment of recurrent aphthous ulcers with Aureomycin mouth rinse or Zendium dentifrice. *Acta Odontol Scand.* 1985 Mar;43(1):47-52
- Lo Muzio L, della Valle A, Mignogna MD, Pannone G, Bucci P, Bucci E, Sciubba J. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. *J Oral Pathol Med.* 2001 Nov;30(10):611-7.
- Nolan A, Baillie C, Badminton J, Rudralingham M, Seymour RA. The efficacy of topical hyaluronic acid in the management of recurrent aphthous ulceration. *J Oral Pathol Med.* 2006 Sep;35(8):461-5.
- Porter SR, Al-Johani K, Fedele S, Moles DR. Randomised controlled trial of the efficacy of HybenX in the symptomatic treatment of recurrent aphthous stomatitis. *Oral Dis.* 2009 Mar;15(2):155-61
- Porter S, Scully C. Aphthous ulcers: recurrent. *Clin Evid.* 2005 Jun;(13):1687-94.
- Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. *Cochrane Database of Systematic Reviews* 2011, Issue 7. Art. No.: CD001168. DOI: 10.1002/14651858.CD001168.pub2.
- Ungphaiboon S, Nittayananta W, Vuddhakul V, Maneenuan D, Kietthubthew S, Wongpoowarak W, Phadoongsombat N. Formulation and efficacy of triamcinolone acetate mouthwash for treating oral lichen planus. *Am J Health Syst Pharm.* 2005 Mar 1;62(5):485-91.

Medel för lokal smärtlindring

- Epstein JB, et al. Benzylamine HCL for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. *Cancer.* 2001;92:875-85.

Medel vid svampinfektion

- Goins RA, Ascher D, Waecker N, Arnold J, Moorefield E. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. *Pediatr Infect Dis J.* 2002;21:1165-7.
- Taillandier J, Esnault Y, Alemanni M. A comparison of fluconazole oral suspension and amphotericin B oral suspension in older patients with oropharyngeal candidosis. *Multicentre Study Group. Age Ageing.* 2000;29:117-23.
- Stafford GD, Arendorf T, Huggett R. The effect of overnight drying and water immersion on candidal colonization and properties of complete dentures. *J Dent.* 1986;14:52-6.

Medel vid bakteriell infektion

- Antibiotikaprofylax för att förebygga endokardit i samband med odontologiska ingrepp. Tandläkartidningen 2016;4:68.
- Läkemedelsverket. Indikationer för antibiotikaprofylax i tandvården – ny rekommendation. Information från Läkemedelsverket 2012;5:22-35. <https://www.lakemedelsverket.se>
- Läkemedelsverket. Rekommendationer för antibiotikabehandling i tandvården. Information från Läkemedelsverket 2014;1:19-30. <https://www.lakemedelsverket.se>
- National Institute for Health and Care Excellence (NICE). Prophylaxis against infective endocarditis: Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. Issued: March 2008 last modified: September 2015. NICE clinical guideline 64. <https://www.nice.org.uk>
- Rekommendation för antibiotika till patienter som strålbehandlats mot munhålan. Tandläkartidningen 2016;5:58-59.
- Socialstyrelsen. National Guidelines for Adult Dental Care 2011. www.socialstyrelsen.se/nationalguidelines (21 november 2016)
- 2015 ESC Guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2015;36(44):3075–128.

Medel vid herpesvirusinfektion

- Arain N, Paravastu SC, Arain MA. Effectiveness of topical corticosteroids in addition to antiviral therapy in the management of recurrent herpes labialis: a systematic review and meta-analysis. BMC Infect Dis. 2015 Feb 21;15:82.
- Chi CC1, Wang SH, Delamere FM, Wojnarowska F, Peters MC, Kanjirath PP. Interventions for prevention of herpes simplex labialis (cold sores on the lips). Cochrane Database Syst Rev. 2015 Aug 7;8:CD010095.
- Harmenberg J, Arlander E, Aoki F, Bring J, Darpö B, Levin MJ, Tyring S, Spruance SL; ME-609 Study Group. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol. 2011 Apr;64(4):696.e1-11.

Läkemedelsrelaterad käkbensnekros, MRONJ (Medication-Related Osteonecrosis of the Jaws)

- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56.

Referenser Neurologi 2018

Epilepsi

Cochrane metaanalys 2017

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011412.pub2/full>

Glauser et al, *Epilepsia* 2006 jul; 47(7): 1094-120: ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes

Helmstaedt C, Witt JA. *Epilepsy Behav.* 2010 May;18(1-2):74-80: Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: a non-interventional surveillance trial.

Läkemedelsverkets behandlingsrekommendationer, epilepsi. 2011 (22) 1. <http://www.lakemedelsverket.se/malgrupp/Halso--sjuk-vard/Behandlings-rekommendationer/Behandlingsrekommendation--listan/Epilepsi/>

Marson et al, *Lancet* 2007 Mar 24; 369: 1000-1026: The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.

Marson AG, Kadir ZA, Hutton JL, Chadwick DW. *Epilepsia.* 1997 Aug;38(8):859-80: The new antiepileptic drugs: a systematic review of their efficacy and tolerability.

Marson AG, Hutton JL, Leach JP, Castillo S, Schmidt D, White S, Chaisewikol R, Privitera M, Chadwick DW. *Epilepsy Res.* 2001 Sep;46(3):259-70: Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review.

Meador KJ, Gevins A, Loring DW, McEvoy LK, Ray PG, Smith ME, Motamedi GK, Evans BM, Baum C. *Neurology.* 2007 Nov 27;69(22):2076-84: Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam.

Migrän

Nezvalová-Henriksen, K; Spigset, O; Nordeng, H *Eur. J. Epidemiol.*, 2013 vol. 28(9) pp. 759-69 Triptan safety during pregnancy: a Norwegian population registry study

Källén, B; Nilsson, E; Otterblad Olausson, P *Drug Saf.* 2011 vol. 34(8) pp. 691-703 Delivery outcome after maternal use of drugs for migraine: a register study in Sweden

Stovner LJ, Linde M, Gravidahl GB, et al. *Cephalalgia* 2013; 34: 523–32. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.

Parkinson

Läkemedelsverkets behandlingsrekommendationer vid Parkinsonism, 2008

<http://www.lakemedelsverket.se/malgrupp/Halso--sjukvard/Behandlings-rekommendationer/Behandlingsrekommendation--listan/Parkinsonism/>

PD MED Collaborative Group, *Lancet.* 2014 Sep 27;384 (9949):1196-205 Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.

Sekundärprofylax efter stroke/TIA

Adam et al, *Ann Intern Med* 2012 Aug 28, Epub ahead of print, Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.

Boulouis et al, *J Neurol Neurosurg Psychiatry.* 2017 Oct 13. pii: jnnp-2017-316631. doi: 10.1136/jnnp-2017-316631, Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis.

Camm et al, *Eur Heart J.* 2012 Aug 24, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation

Connolly et al, *N Engl J Med* 2009 Sep 17;361(12):1139-51, Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY trial). CURRENT-OASIS 7 Investigators, *N Engl J Med* 2010;363:930-42. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary

Syndromes

Diener et al, *J Neurol Sci* 1996;143:1-13, European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

Diener et al, *Lancet*, 364 (2004), pp. 331–337, Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) randomized, double-blind, placebo-controlled trial

Diener et al, *Lancet Neurol* 2010; 9: 1157–63, Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

Halkes et al, ESPRIT Study Group, *Lancet* 2006;367:1665–1673, Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin

(ESPRIT): randomised controlled trial.

Friberg, Oldegren, *Open Heart* 2017;4:e000682. doi:10.1136/openhrt-2017-000682 Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation

Gorelick et al, *Stroke Research and Treatment*, Volume 2013, Article ID 727842 Review Article: Advances in Our Understanding of "Resistance" to Antiplatelet Agents for Prevention of Ischemic Stroke

Granger et al, *N Engl J Med* 2011 Sep 15;365(11):981-92, Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE trial) Olesen et al, *Thrombosis and Hemostasis* 2011; 106: 739-749 Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Guigliano et al, *N Engl J Med* 2013 Nov 28;369(22):2093-104, Edoxaban versus warfarin in patients with atrial fibrillation

Huhtakangas et al,

1	
---	--

 See comment in PubMed Commons below *Int J Stroke*. 2015 Aug;10(6):876-81, Improved survival of patients with warfarin-associated intracerebral haemorrhage: a retrospective longitudinal population-based study

Johnston et al, *N Engl J Med*. 2016 Jul 7;375(1):35-43, Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack

Kermer et al, *Int J Stroke*. 2017 Jun;12(4):383-391, Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.

Läkemedelsverket, Information från läkemedelsverket 1:2017 Antikoagulantbehandling vid förmaksflimmer – behandlingsrekommendation https://lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/Info_fran_LV_nr_1_2017_behandlingsrekommendation_webbpublicering.pdf

Ntaos et al, *Stroke*. 2017;48:2494-2503 Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonist for Stroke Prevention in Atrial Fibrillation. A Systematic Review and Meta-Analysis

Parry-Jones et al, *Ann Neurol*. 2015 Jul;78(1):54-62, Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage.

Patel et al, *N Engl J Med* 2011;365:883-91, Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET-AF trial)

Pink et al, *BMJ* 2011, Oct 31; 343, Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Pollack et al, *N Engl J Med*. 2017 Aug 3;377(5):431-441, Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.

Reddy et al,

1	
---	--

 See comment in PubMed Commons below *J Am Coll Cardiol*. 2017 Nov 4. pii: S0735-1097(17)41187-9, 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.

Rothwell et al, *Lancet*. 2007 Oct 20;370(9596):1432-42, Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison.

Sacco et al, *N Engl J Med* 2008 Sep 18;359(12):1238-51. Epub 2008 Aug 27, Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke (PROFESS study).

Saxena et al, *The Cochrane Library* 2008, Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack

Schulz, U.G., Drug treatments in the secondary prevention of ischaemic stroke. *Maturitas*, 2013; p. 10.1016/j.maturitas.2013.05.009.

Socialstyrelsen, Nationella riktlinjer för vård vid stroke 2017 <http://www.socialstyrelsen.se/publikationer2017/2017-5-13/>

Wallentin et al, Lancet 2010; 376: 975-83: Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

Wang et al, N Engl J Med 2013;369:11-19. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack

Webb, A.J., et al., Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet, 2010. 375(9718): p. 906-15.

RLS

Romenets, S.R. and R.B. Postuma, Treatment of Restless Legs Syndrome. Current Treatment Options in Neurology, 2013(DOI 10.1007/s11940-013-0241-x).

Garcia-Borreguero, D., et al., European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol, 2012. 19(11): p. 1385-96.

Garcia-Borreguero, D., et al., The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med, 2013. 14(7): p. 675-84.

Aurora, R.N., et al., The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.

Sleep, 2012. 35(8): p. 1039-62.

Referenser Osteoporos

TA087 Osteoporosis – secondary prevention – NICE Guidance. January 2005. <http://www.nice.org.uk>. Accessed 3rd January 2005.

Nationella riktlinjer för rörelseorganens sjukdomar 2012. Osteoporos, artros, inflammatorisk ryggsjukdom och ankyloserande spondylit, psoriasisartrit och reumatoid artrit. Socialstyrelsen 2012. ISBN: 978-91-87169-32-8.

Ernst E et al. Exercise for female osteoporosis. A systematic review of randomised clinical trials. *Sports med* 1998;25:359-68.

Van Schoor NM et al. Prevention of hip fractures by external hip protectors a randomised controlled trial. *JAMA* 2003;289:1957-62.

Epidemiologi och diagnos

Evaluation of decision rules for referring women for bone densitometry by dual x-ray absorptiometry. *JAMA* 2001;286:57-62

Cummings et al. Bone density at various sites for prediction of hip fractures. *Lancet* 1993;341:72-5.

Garnero et al. Markers of bone turnover for the prediction of fracture risk. *Osteoporosis Int* 2000;11:55-56.

Kanis JA, Johnell O, Oden et al. Ten year probabilities of osteoporotic fracture according to BMD and diagnostic threshold. *Osteoporosis Int*. 2001;12:989-95.

Kanis JA, Johnell O, Oden et al. FRAX and the assessment of fracture probability in men and women from the UK. *Osteop Int*. 2008 Apr;19(4):385-97.

Law et al. A meta-analysis of smoking, bone mineral density and risk of hip fracture: recognition of a major effect. *BMJ* 1997;315:841-6.

Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 1996;312:1254-1259.

Versluis RG, Papapoulos SE, de Bock GH et al. Clinical risk factors as predictors of how well measures of bone density predict occurrence of osteoporosis in general practice. *BJGP* 2001;51:806-10

Watts NB. The fracture risk assessment tool (FRAX): applications in clinical practice. *J Womens health (Larchmt)*. 2011 Apr;20(4):525-31.

Behandling

Adler R, Ghada El-Hajj F, Bauer D et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. *JBMR* 2016 Jan. Vol 31, no 1, 16-35.

Cranney A, Guyatt G, Griffith L, et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. *Endocr Rev*. 2002 Aug;23(4):570-8.

Cranney A, Weiler HA, O'Donnell S, Pui L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. *Am J Clin Nutr*. 2008 Aug;88(2):513S-519S. Review.

Avenell A, Mak JCS, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men (Review) *Cochrane Database of Systematic Reviews* 2014, Issue 4.

Devogelaer JP, Goemare S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. *Osteop Int*. 2006 Jan;17(1):8-19.

Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. *Osteop Int* 2003;14:2-12.

McClung M, Harris S et al. Bisphosphonate therapy for osteoporosis; benefits, risks and drug holiday. *Am J Med*. 2013 Jan;126(1):13-20.

Reginster J. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. *Drugs* 2011;71(1); 65-78.

Bisfosfonater

McClung et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. *NEJM* 2001;344:333-40

Devogelaer JP et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. *Osteoporos Int*. 2007;18(9):1211-8.

Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. *Arch Intern Med*. 2006;166(11):1209-17.

Silverman S. L. et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study. *Osteoporos Int* (2007) 18:25.

Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med*. 2007;356(18):1809-22.

Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med*. 2007;357(18):1799-809.

Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev*. 2008 Jan 23;(1):CD004523. Review.

Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev*. 2008 Jan 23;(1):CD001155. Review.

Schilcher J, Michaëlsson K, Aspenberg P; Bisphosphonate use and atypical fractures of the femoral shaft. *N Engl J Med* 2001;362:1728-37.

Raloxifen

Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. *Endocr Rev*. 2002 Aug;23(4):524-8. Review.

Strontium

Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral osteoporosis (TROPOS) Study. *J Clin Endocrinol Metab*. 2005;90(5):2816-22.

PTH

Cranney A, Papaioannou A, Zytaruk N, et al; Clinical Guidelines Committee of Osteoporosis Canada. Parathyroid hormone for the treatment of osteoporosis: a systematic review. *CMAJ*. 2006;175(1):52-9. Review.

Greenspan SL, Bone HG, Ettinger MP, et al; Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. *Ann Intern Med*. 2007;146(5):326-39. Summary for patients in: *Ann Intern Med*. 2007;146(5):I20.

Denosumab

McClung MR, Lewiecki EM, Cohen SB et al. AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. *N Engl J Med*. 2006;354(8):821-31.

Cummings SR, San Martin J, McClung MR et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*. 2009;361(8):756-65. Erratum in: *N Engl J Med*. 2009 Nov 5;361(19):1914.

Smith MR, Egerdie B, Hernández Toriz N et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med*. 2009;361(8):745-55.

Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol*. 2010;28(35):5132-9.

Miller PD, Wagman RB, Peacock M et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. *J Clin Endocrinol Metab* 2011 Feb;96(2):394-402.

Vitamin D

Lorentzon M, Åkesson K, Mellström D et al. D-vitaminbehandling och skeletthälsa – svenska riktlinjer behövs. Rekommendationer från svenska osteoporossällskapet kliniska expertgrupp. *Läkartidningen*. 2014;111;CW6C:1-4.

Maier S, Sidelnikov E, Dawson-Hughes B et al. Before and after hip fracture, vitamin D deficiency may not be treated sufficiently. *Osteoporos Int* 2013;24:2765-73.

Referenser Psykiatri

- Allgulander, C et al: Nytt och risker med bensodiazepiner. Aktuell faktaanlys, Läkartidningen 2011 nr 41 sid 2025-9; <http://www.lakartidningen.se/>
- Behandling av alkoholabstinens - en uppdatering av evidensläget efter SBU-rapporten, 2010. https://lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/bakg_dok/Bakgrund_alkoholabstinens_bokm%C3%A4rken.pdf
- Behandling av alkohol- och narkotikaproblem, SBU-rapport nr 156 (2 volymer) 2001; <http://www.sbu.se/sv/publikationer/SBU-utvardeerar/behandling-av-alkohol-och-narkotikaproblem/>
- Läkemedelsbehandling vid alkoholberoende (Läkemedelsverket 2007;18 (1)); https://lakemedelsboken.se/kapitel/beroendetillstand/alkohol-riskbruk_missbruk_och_beroende.html
- National Institute of Clinical Excellence: Clinical Guidelines CG115 Issued Feb 2011, Alcohol Use Disorders: diagnosis, assessment and management av harmful drinking and alcohol dependence; <https://www.nice.org.uk/guidance/cg115>
- Nationella riktlinjer för vård och stöd vid missbruk och beroende – Stöd för styrning och ledning; <http://www.socialstyrelsen.se/publikationer2015/2015-4-2>
- Practice Guideline for The Treatment of Patients With Substance Use Disorders, Second Edition, American Psychiatric Association https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse.pdf
- Socialstyrelsens föreskrifter och allmänna råd om läkemedelsassisterad underhållsbehandling vid opiatberoende (SOSFS 2011:9); <https://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/20053/2016-2-3.pdf>
- 2011-11-22: SBU-rapporter ang behandling med naltrexon och akamprosot vid alkoholberoende: <http://www.sbu.se/sv/publikationer/sbu-kommentar/behandling-med-akamprosot-vid-alkoholberoende/>, <http://www.sbu.se/sv/publikationer/sbu-kommentar/behandling-med-naltrexon-vid-alkoholberoende/>
- Tema Riskbruk, Missbruk, Beroende, Läkartidningen nr 45 2011 volym 108, pp 2279- 2315; <http://ww2.lakartidningen.se/store/artic-lepdf/1/17300/LKT1145s2279.pdf>
- Pharmacotherapy for alcohol dependence: status of current treatment Johan Franck and Nitya Jayaram-lindström 2013, <http://www.sciencedirect.com/science/article/pii/S0959438813001190>

Bipolära syndrom:

- (Merikangas et al., 2007 Merikangas KR, Akiskal HS, Angst J, et al. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 64:543–552.).
- (Barnett och Smoller, 2009 Barnett JH, Smoller JW (2009) The genetics of bipolar disorder. Neuroscience, 164:331-343 och SPF)
- Svenska psykiatriska föreningen (SPF) <http://www.svenskpsykiatri.se/>
- Affektiva symptom är dödliga – självmordsrisken är hög <http://www.lakartidningen.se/Functions/OldArticleView.aspx?articleId=19316>
- SBU <http://www.sbu.se/sv/sok/?q=bipol%C3%A4r+sjukdom>
- Läkemedelsverket Behandlingsrekommendationen om depression, ångest och tvångssyndrom
- <https://lakemedelsverket.se/malgrupp/Halso--sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation--listan/Depression-angestsyndrom-och-tvangssyndrom-hos-barn-och-vuxna/>
- Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. [http://www.jaacap.com/article/S0890-8567\(14\)00891-0/fulltext](http://www.jaacap.com/article/S0890-8567(14)00891-0/fulltext)
- Lithium in the acute treatment of bipolar I disorder: a double-blind placebo-controlled study
- <http://pediatrics.aappublications.org/content/early/2015/10/06/peds.2015-0743>
- A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical problem <http://journals.sagepub.com/doi/abs/10.1177/070674370705200606>
- S3-Leitlinie zur Diagnostik und Therapie Störungen <https://link.springer.com/article/10.1007/s00115-011-3415-3>
- Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. <http://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.161.2.217>
- A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I) <http://www.psychiatrist.com/JCP/article/Pages/2010/v71n02/v71n0206.aspx>
- Effects of chronic lithium treatment on renal function <http://www.sciencedirect.com/science/article/pii/S016503271000354X>

- Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry <http://www.sciencedirect.com/science/article/pii/S016503271000354X>
- Principles of antiepileptic drug action https://books.google.se/books?id=HAOY0qG-vAYC&pg=PA3&lpg=PA3&dq=Principles+of+antiepileptic+drug+action%22.&source=bl&ot-s=xJG0WRdhHj&sig=EqSFobX0qyPS3Jetzn1mCCGw04&hl=sv&sa=X&ved=0OahUKewjYo_WljaXWAhWIF5oKHbwqC-sQ6AEIMzAB#v=onepage&q=Principles%20of%20antiepileptic%20drug%20action%22.&f=false
- Risperidone long-acting injectable (Risperdal Consta(R)) for maintenance treatment in patients with bipolar disorder <https://www.ncbi.nlm.nih.gov/pubmed/20977322>
- Depot antipsychotic medications in bipolar disorder: a review of the literature https://www.researchgate.net/publication/6152047_Depot_antipsychotic_medications_in_bipolar_disorder_A_review_of_the_literature?ev=publicSearchHeader&_sg=ELzcjPVI8FFeBMYUtnzPvOXway3mJ-QEZBgT5A34B12ecqUi5Z8SncBohO7EW_x2WdCwxKQImp2qzDI
- Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration <http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0447.2008.01237.x/full>

Depression:

- Behandling av depressionssjukdomar, SBU-rapport nr 166 (2 volymer) 2004; <http://www.sbu.se/sv/publikationer/SBU-utvardeerar/behandling-av-depressionssjukdomar/>
- Bergen H et al: A comparative study of non-fatal self-poisoning with antidepressants relative to prescribing in three centres in England; *J Affect Disord.* 2010 Jun;123(1-3):95-101. Epub 2009 Oct 28; <http://www.sciencedirect.com/science/article/pii/S0165032709004649>
- Combining Medications to Enhance Depression Outcomes (CO-MED Study): <http://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.2011.10111645>
- European Medicines Agency (EMA): Pharmacovigilance Working Party (PhVWP), 27 October 2011 http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/10/WC500117061.pdf (citalopram)
- European Medicines Agency (EMA): Pharmacovigilance Working Party (PhVWP), 24 November 2011; http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/11/WC500117988.pdf (escitalopram)
- H. Lundbeck AB; (s k "Dear Doctor"-letter till hälsovårdspersonal, Cipramil och Citalopram CNSPharma (citalopram hydrobromid) associerade med dosberoende förlängning av QT-intervall; personligt informationsbrev till alla svenska förskrivare daterat den 26 oktober 2011 undertecknat av Sofia Lagerholm, Regulatory Affairs Manager, H. Lundbeck AB
- H. Lundbeck AB; (s k "Dear Doctor"-letter till hälsovårdspersonal, Escitalopram (Cipralox) associerat med dosberoende förlängning av QT-intervall; personligt informationsbrev till alla svenska förskrivare daterat den 5 december 2011 undertecknat av Anders Luts, Medicinsk Chef, H. Lundbeck AB, Sverige
- Howell C, Wilson A D, Waring W S: Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases, *Br J Clin Pharmacol.* 2007 Aug;64(2):192-7. Epub 2007 Feb 12; <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2007.02849.x/full>
- Depression, ångestsyndrom och tvångssyndrom hos barn och vuxna 2016; <https://lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation---listan/Depression-angestsyndrom-och-tvangssyndrom-hos-barn-och-vuxna/>
- Farmakologisk depressionsbehandling i primärvården – några typfall, poster utformad av Terapigrupp Psykiatri Region Skåne december 2011; <http://vardgivare.skane.se/contentassets/acb0b3c62e2a47aca7379b3829df804f/farmakologisk-depressionsbehandling-i-primarvar-den--nagra-typfall.pdf>
- Hayes BD: Comparison of toxicity of acute overdoses with citalopram and escitalopram; *J Emerg Med* 2010 Jul;39(1):44-8. Epub 2008 Dec 11; <http://www.sciencedirect.com/science/article/pii/S0736467908006677>
- Hawton K et al: Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose, *Br J Psychiatry.* 2010 May;196(5):354-8; <http://bjp.rcpsych.org/content/196/5/354>
- Kelly C A et al: Comparative toxicity of citalopram and the newer antidepressants after overdose, *J Toxicol Clin Toxicol.* 2004;42(1):67-71; <http://www.tandfonline.com/doi/abs/10.1081/CLT-120028747>
- Läkemedelsverket: Citalopram – sänkt maxdos rekommenderas, 27 oktober 2011; <https://lakemedelsverket.se/Alla-nyheter/NYHETER-2011/Citalopram--sankt-maxdos-rekommenderas/>
- Läkemedelsverket: Escitalopram – sänkt maxdos för äldre rekommenderas, 27 november 2011 <https://lakemedelsverket.se/Alla-nyheter/NYHETER-2011/Escitalopram--sankt-maxdos-for-aldre-rekommenderas/>
- Mohammed R et al: Prolonged QTc interval due to escitalopram overdose; *J Miss State Med Assoc.* 2010 Dec;51(12):350-3; <https://www.ncbi.nlm.nih.gov/pubmed/21370605>
- National Institute Of Clinical Excellence (NICE guidelines issued October 2009) CG90 Depression: Depression: the treatment and management of depression in adults (update); <https://www.nice.org.uk/guidance/CG90>

- Odar-Cederlöf I et al: Citalopram inte riskfritt från hjärtsynpunkt. SSRI-preparat kan ge förlängd QTc-tid Läkartidningen 2006 nr 14 sid 1112-4; <http://lakartidningen.se/>
- Personne M et al: Toxicitet vid överdosering av nya antidepressiva. Genomgång av epikrismaterial visar olika svår symtombild för olika medel Läkartidningen 2008 nr 3 sid 125-7; http://ww2.lakartidningen.se/store/articlepdf/8/8558/LKT0803s125_127.pdf
- Practice Guideline for The Treatment of Patients With Major Depressive Disorders , American Psychiatric Association November 2010; https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
- Rush AJ et al: Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report, Am J of Psychiatry, Nov 2006; 163; 1905-1917; <http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.2006.163.11.1905>
- Rush AJ : STAR*D: What Have We Learned?, Am J Psychiatry, Feb 2007; 164: 201 – 204; <http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.2007.164.2.201>
- Rush AJ et al: Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study; Am J of Psychiatry, July 2011; 168; 689-701; <http://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2011.10111645>
- SBU: Diagnostik och uppföljning av förstämningssyndrom (20121107); <http://www.sbu.se/sv/publikationer/SBU-utvardear/diagnostik-och-uppfoljning-av-forstamningssyndrom/>
- Socialstyrelsen: Nationella riktlinjer för depressionssjukdom och ångestsyndrom – beslutsstöd för prioriteringar (2010); www.socialstyrelsen.se/publikationer2010/2010-3-4
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study: <https://www.nimh.nih.gov/funding/clinical-research/practical/stard/index.shtml>
- TLV - Cymbalta ingår även fortsättningsvis i högkostnadsskyddet med begränsning 2012; <http://www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/cymbalta1/>
- TLV – genomgång av läkemedel mot depression (december 2008); <http://www.tlv.se/Upload/Genomgangen/slutrapport-depression.pdf>
- US. Food and drug Administration (FDA); Celexa (citalopram hydrobromide): Drug Safety Communication - Abnormal Heart Rhythms Associated With High Doses (Posted 24th August 2011); <http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm>
- Venlafaxine– Summary of basis for regulatory position (2006 - 2011) <https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency> (sök på venlafaxine så kommer olika sammanfat- tande riktlinjer upp)
- <https://crediblemeds.org/> (kontinuerligt uppdaterade hemsidor med listor över läkemedel med potentiell påverkan på QT-intervall med värdering av arytmirisk, dvs ffa torsade de pointes)
- US Food and Drug Administration (FDA): <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/>
- 2011-11-21: TLV:s utvärdering av förmånen beträffande duloxetin (Cymbalta): www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/cymbaltas-uppfoljningsvillkor-uppfyllt
- <https://clinicaltrials.gov/>
- <http://www.ema.europa.eu/ema/>
- A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors <http://www.nature.com/tp/journal/v6/n6/abs/tp2016104a.html>

Neuropsykiatriska sjukdomstillstånd:

- Jankovic J: Tourette's syndrome, N Engl J Med 2001 Oct 18;345(16):1184-92; <http://www.nejm.org/doi/full/10.1056/NEJMra010032>
- Läkemedelsbehandling vid ADHD (Läkemedelsverket 2009); <https://lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation---listan/Adhd/>
- Silay YS; Jankovic J: Emerging drugs in Tourette syndrome, Expert Opin Emerg Drugs. 2005 May; 10(2):365-80; <http://www.tandfonline.com/doi/abs/10.1517/14728214.10.2.365>
- 2012-01-11: SBU rapport om bristfällig dokumentation vid utredning och behandling av ADHD & autism: <http://www.sbu.se/sv/pressmeddelanden/tidigare-pressmeddelanden/2012/adhd/>
- SBU: Diagnostik och behandling av ADHD och autismspektrumtillstånd; - <http://www.sbu.se/sv/publikationer/SBU-utvardear/adhd-diagnostik-och-behandling-vardens-organisation-och-patientens-delaktighet/>
- ADHD och autismspektrumstörning i ett livsperspektiv : en klinisk introduktion till utvecklingsrelaterade kognitiva funktionsproblem Gunilla Thernlunds <http://www.tlv.se/>

Psykotiska symtom/schizofreni:

- Schizofreni – behandlingsrekommendation; Läkemedelsverket 2013
<https://lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation---listan/Schizofreni-1/>
- World Federation of Societies of Biological Psychiatry (WFSBP)
Guidelines for Biological Treatment of Schizophrenia, Part 2:
Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects;
http://www.wfsbp.org/fileadmin/user_upload/Treatment_Guidelines/WFBSP_SZ_Guidelines_Part2_2013.pdf
- Dixon, L et al: uppdatering av Guideline Watch (September 2009): APA Practice Guideline for the Treatment of Patients With Schizophrenia;
http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia-watch.pdf
- Guidelines for Biological Treatment of Schizophrenia, part 1: Acute Treatment of Schizophrenia – 2005 (World Federation of Societies of Biological Psychiatry (WFSBP); World J Biol Psychiatry 2005;6(3):132-191; <http://www.tandfonline.com/doi/abs/10.1080/15622970510030090>
- Kane J M, Leucht S, Carpenter D, Docherty J P. The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders. Journal of Clinical Psychiatry 2003;64 (suppl 12):1-100; http://www.uio.no/studier/emner/matnat/farmasi/FRM2410/v06/undervisningsmateriale/psykosor_behandling_artikler/concensus_treatment_schizophrenia.pdf
- Msghina M et al: Antipsykotiska läkemedel väljs bäst efter biverkningsprofil; Läkartidningen nr 44 vol 106 2009;2841-46; <http://lakartidningen.se/>
- National Institute Of Clinical Excellence (NICE guideline update February 2014) CG178 Schizophrenia: Psychosis and schizophrenia in adults: prevention and management (NICE guideline) ; <https://www.nice.org.uk/guidance/cg178>
- Practice Guideline for The Treatment of Patients With Schizophrenia, Second Edition, American Psychiatric Association April 2004; <https://uncc.pure.elsevier.com/en/publications/practice-guideline-for-the-treatment-of-patients-with-schizophre>
- SBU: Schizofreni – Läkemedelsbehandling, patientens delaktighet och vårdens organisation (20121121) ; http://www.sbu.se/contentassets/3908bd4317a1421fb091eae098b150bb/schizofreni_2012.pdf
- Svenska Psykiatriska Föreningens kliniska riktlinjer: Att förebygga och handlägga metabol risk hos patienter med allvarlig psykisk sjukdom; <http://www.svenskpsykiatri.se/documents/2010/metabolrisk.pdf>
- Svenska Psykiatriska Föreningens kliniska riktlinjer: Schizofreni - kliniska riktlinjer för utredning och behandling; http://www.svenskpsykiatri.se/Riktlinjer/rp_schizofreni_tryck.pdf
- Thelander Sten et al; Läkemedel mot schizofreni: SBU lyckas inte reda ut begreppen (jämte) Replik: SBU står fast - läkemedel räddar liv vid schizofreni av Mats Berglund, Eva Lindström, Mikael Nilsson, Måns Rosén Läkartidningen 2012 nr 32 sid 1417-9; <http://lakartidningen.se/>
- Antipsykotiska läkemedel: läkartidningen.2014;111:CY3U; <http://lakartidningen.se/>

Sömnstörning:

- Behandling av sömnbesvär hos vuxna (SBU 2010); http://www.sbu.se/contentassets/ffa024035dbd440ea1c9c71fff1748ec/behandling_somnbesvar_vuxna_fulltext.pdf
- Dunder Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T: Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis, Hum Psychopharmacol. 2004 Jul;19(5):305-22; <http://onlinelibrary.wiley.com/doi/10.1002/hup.594/abstract>
- Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W: Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data, Addiction. 2003 Oct;98(10):1371-8; <http://onlinelibrary.wiley.com/doi/10.1046/j.1360-0443.2003.00491.x/full>
- S J Wilson et al: British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders, J Psychopharmacol published online 2 September 2010; <http://journals.sagepub.com/doi/pdf/10.1177/0269881110379307>
- Läkemedelsverket 2014; Nya rekommendationer för att minska risken för nedsatt körförmåga dagen efter intag av zolpidem; <https://lakemedelsverket.se/Alla-nyheter/NYHETER-2014/Nya-rekommendationer-for-att-minska-risken-for-nedsatt-korformaga-dagen-efter-intag-av-zolpidem/>

Ångestsyndrom (inkl tvångssyndrom och posttraumatiskt stressyndrom)

- Allgulander, C et al: Nyttan och risker med bensodiazepiner. Aktuell faktaanlys Läkartidningen 2011 nr 41 sid 2025-9; <http://lakartidningen.se/>
- Depression, ångestsyndrom och tvångssyndrom hos barn och vuxna – behandlingsrekommendation Läkemiddelsverket 2016; <https://lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation---listan/Depression-angestsyndrom-och-tvangssyndrom-hos-barn-och-vuxna/>
- Socialstyrelsen: Nationella riktlinjer för depressionssjukdom och ångestsyndrom – beslutsstöd för prioriteringar (2010); HYPERLINK "<http://www.socialstyrelsen.se/publikationer2010/2010-3-4>"
- Ångestsjukdomar hos barn och ungdomar – hjälp finns att få; Läkartidningen nr 43-44 Oktober 2012; 1946-49; <http://lakartidningen.se/>
- Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder:
- A revision of the 2005 guidelines from the British Association for Psychopharmacology <http://journals.sagepub.com/doi/full/10.1177/0269881114525674>
- Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders (review) <http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD005473.pub2/full>

Referenser Smärta

Akut smärta

Oxford league table of analgesics in acute pain (2007). Bandolier. www.medicine.ox.ac.uk/bandolier/booth/painpag/Acutrev/Analgesics/lftab.html.

Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. *JAMA* 1995;273(12):929-33.

Oxycodone for the treatment of postoperative pain. Kokki H, Kokki M, Sjövall S. *Expert Opin Pharmacother*. 2012 May;13(7):1045-58. Review. PMID: 22519769 [PubMed - indexed for MEDLINE] Related citations

Long-acting morphine following hip or knee replacement: a randomized, double-blind and placebo-controlled trial. Musclow SL, Bowers T, Vo H, Glube M, Nguyen T. *Pain Res Manag*. 2012 Mar-Apr;17(2):83-8. PMID: 22518369 [PubMed - indexed for MEDLINE] Related citations

Lin J, et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. *BMJ*. 2004;329(7461):324.

Mason L, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. *BMC Musculoskelet Disord*. 2004;5(1):28.

Nabulsi M, Tamim H, Sabra R, Mahfoud Z, Malaeb S, Fakhri H, Mikati M. Equal antipyretic effectiveness of oral and rectal acetaminophen: a randomized controlled trial. *BMC Pediatr*. 2005;5:35.

Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. *Arch Pediatr Adolesc Med* 2004;158(6):521-6.

Långvarig smärta, allmänt

Artros. Behandling av artros. Läkemedelsverket och Statens Legemiddelverk. Information från Läkemedelsverket 2004;15(3):19-75.

www.lakemedelsverket.se (Hälsa- och sjukvård/ Behandlingsrekommendationer/Artros)

SBU rapport nr 177 (2006). Metoder för behandling av långvarig smärta. En systematisk litteraturoversikt. www.sbu.se

Läkemedelsbehandling av långvarig smärta hos barn och vuxna – behandlingsrekommendation. Information från Läkemedelsverket 2017;28(3):23–53.

Långvarig smärta, COX-hämmare

Bresalier RS et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 2005;352:1092-102.

Chan FK et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. *N Engl J Med* 2002;347:2104-10.

Chan FK et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. *Gastroenterology*. 2004;127:1038-43.

Chan FK, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. *Lancet* 2007;369(9573):1621-6.

Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. *Br J Clin Pharmacol*. 2003;55(6):591-5.

Coxib and Traditional NSAID Trialists' Collaboration. The Lancet ;Early Online Publication, 30 May 2013. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *The Lancet*.

EMA (European Medicines Agency): CHMP review on non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Opinion, and Appendix II. EMA/CHMP/410051/2006. <http://www.emea.eu.int/humans/opiniongen/nsaids06.htm> (verifierat 2006-12-06)

Helin-Salmivaara A, et al. Risk of upper gastrointestinal events with the use of various NSAIDs: a case-control study in a general population. *Scand J Gastroenterology* 2007;42:923-32 (a)

Helin-Salmivaara A, et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. *Eur J Clin Pharmacol* 2007;63:403-6 (b)

Hooper L, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. *BMJ*. 2004;329(7472):948.

Lin J, et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. *BMJ*. 2004;329(7461):324.

Mason L, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. *BMC Musculoskelet Disord*. 2004;5:28.

Rostom et al. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2002. Oxford: Update Software. (Date of most recent substantive amendment: 24 August 2004)

Solomon SC et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 2005;352:1071-80.

Tata LJ et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? *Aliment Pharmacol Ther*. 2005;22(3):175-81.

Towheed TE et al. Acetaminophen for osteoarthritis. *Cochrane Database Syst Rev*. 2006 Jan 25;(1):CD004257.

Långvarig smärta, opioider

Davis MP et al. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy (Review). *Support Care Cancer* 2003;22:84-92.

Opioider. Användning av opioider vid långvarig icke-cancerrelaterad smärta. Läkemedelsverket och Statens Legemiddelverk. Workshop. Information från Läkemedelsverket 2002 (1): 17 -75. www.lakemedelsverket.se

Reid CM, et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. *Arch Intern Med* 2006;166(8):837-43.

Riley et al. No pain relief from morphine? *Support Care Cancer* (2006) 14:56–64. Oral morphine for cancer pain (Review). *The Cochrane Collaboration* 2009, Issue 3.

www.lakemedelsverket.se/upload/om-lakemedelsverket/publikationer/lakemedelsboken/LB-2011-2012/Tarmkanalens%20funktionsrubbnigar.pdf

Neuropatisk smärta

Attal N, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. *Eur J Neurol*. 2006;13(11):1153-69.

Finnerup NB et al. Algorithm for neuropathic pain treatment: An evidence based proposal. *Pain*. 2005;118(3):289-305.

Hempstead K et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. *PLoS Med* 2005;2(7):e164.

Neuropatisk smärta. Behandlingsrekommendationer. Läkemedelsverket 2007.

Smärtlindrande läkemedel till äldre

Bannwarth B et al. Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. *J Rheumatol*. 2001;28(1):182-4.

Davis MP, et al. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy (Review). *Support Care Cancer* 2003;22:84-92.

Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids. *World Institute of Pain. Pain Practice*, Volume 8, issue 4, 2008 287 – 313

Review of opioid efficacy in pain management in the elderly. Consensus statement Opioids and the Management of Chronic Severe Pain in the Elderly *Pain Practice*, Volume 8, Issue 4, 2008 287– 313

Utsättning av smärtläkemedel

Haddad PM. Antidepressant discontinuation syndromes. *Drug Saf*. 2001;24:183-97. Norton JW. Gabapentin withdrawal syndrome. *Clin Neuropharmacol*. 2001;24:245-6.

Persson M et al. Utsättningsreaktioner av tramadol – ett större problem än förväntat? Läkemedelsverket 2006-11-14, www.lakemedelsverket.se (2006-12-06)

Pittenger C, Desan PH. Gabapentin abuse, and delirium tremens upon gabapentin withdrawal. *J Clin Psychiatry*. 2007;68(3):483-4.

Tran KT et al. Gabapentin withdrawal syndrome in the presence of a taper. *Bipolar Disord*. 2005;7(3): 302-4.

Barrueto F Jr et al. Gabapentin withdrawal presenting as status epilepticus. *J Toxicol Clin Toxicol*. 2002; 40(7):925-8.

Norton JW. Gabapentin withdrawal syndrome. *Clin Neuropharmacol*. 2001;24(4):245-6. FAS UT 2 Claes Lundgren

Referenser Tandvårdslistan

Medel mot karies

- Ekstrand KR1, Poulsen JE, Hede B, Twetman S, Qvist V, Ellwood RP. A randomized clinical trial of the anti-caries efficacy of 5,000 compared to 1,450 ppm fluoridated toothpaste on root caries lesions in elderly disabled nursing home residents. *Caries Res.* 2013;47(5):391-8.
- Fure S, Gahnberg L, Birkhed D. A comparison of four home-care fluoride programs on the caries incidence in the elderly. *Gerodontology.* 1998;15:51-60
- Griffin SO, Regnier E, Griffin PM, Huntley V. Effectiveness of fluoride in preventing caries in adults. *J Dent Res.* 2007;86:410-415.
- Marinho VCC, Higgins JPT, Logan S, Sheiham A. Fluoride toothpastes for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews* 2003, Issue 1. Art. No.: CD002278. DOI: 10.1002/14651858.CD002278.
- Marinho VCC, Higgins JPT, Logan S, Sheiham A. Fluoride mouthrinses for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews* 2003, Issue 3. Art. No.: CD002284. DOI: 10.1002/14651858.CD002284
- Marinho VCC, Higgins JPT, Logan S, Sheiham A. Fluoride gels for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews* 2002, Issue 1. Art. No.: CD002280. DOI: 10.1002/14651858.CD002280.
- Marinho VCC, Higgins JPT, Logan S, Sheiham A. Fluoride varnishes for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews* 2002, Issue 1. Art. No.: CD002279. DOI: 10.1002/14651858.CD002279.
- Moberg Sköld U, Birkhed D, Borg E, Petersson LG. Approximal caries development in adolescents with low to moderate caries risk after different 3-year school-based supervised fluoride mouth rinsing programmes. *Caries Res.* 2005;39:529- 535.
- Nordström A1, Birkhed D. Preventive effect of high-fluoride dentifrice (5,000 ppm) in caries-active adolescents: a 2-year clinical trial. *Caries Res.* 2010;44(3):323-31.
- SBU. Prevention of Dental Caries. A Systematic review. The Swedish Council on Technology Assessment in Health Care SBU report No161 In Swedish. 2002.
- SBU. Caries Diagnosis, Risk Assessment and Non-operative Treatment of Early Caries Lesions. The Swedish Council on Technology Assessment in Health Care SBU report No 188 In Swedish. 2007.
- Socialstyrelsen. National Guidelines for Adult Dental Care 2011. www.socialstyrelsen.se/nationalguidelines (21 november 2016)
- Walsh T, Worthington HV, Glenny AM, Appelbe P, Marinho VCC, Shi X. Fluoride toothpastes of different concentration for preventing dental caries in children and adolescents. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD007868. DOI: 10.1002/14651858.CD007868.pub2.
- Wyatt CCL, MacEntee MI. Caries management for institutionalized elders using fluoride and chlorhexidine mouthrinses. *Community Dent Oral Epidemiol.* 2004;32:322-328.

Medel för salivstimulering

- LeVeque FG, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. *J Clin Oncol.* 1993;11:1124-1131.
- Vivino FB, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. *Arch Intern Med* 1999;159:174-81.

Antiseptiska medel för lokal behandling

- SBU. Chronic periodontitis – prevention, diagnosis and treatment. Stockholm: Swedish Council on Health Technology Assessment in Health Care (SBU); 2004. SBU report no 169 (in Swedish).

Medel för lokal behandling av munslemhinneförändringar

- Al-Hashimi et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2007;103 Suppl:S25.e1-12.
- Carbone M, Arduino PG, Carrozzo M, Caiazzo G, Broccoletti R, Conrotto D, Bezzo C, Gandolfo S. Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. *Oral Pathol Med* 2009 Feb;38(2):227-33

- Fridh G, Koch G. Effect of a mouth rinse containing amyloglucosidase and glucose oxidase on recurrent aphthous ulcers in children and adolescents. *Swed Dent J*. 1999;23(2-3):49-57
- González-García A, Diniz-Freitas M, Gándara-Vila P, Blanco-Carrión A, García-García A, Gándara-Rey J. Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over-infection. *Oral Dis*. 2006 Nov;12(6):559-65.
- Henricsson V, Axéll T. Treatment of recurrent aphthous ulcers with Aureomycin mouth rinse or Zendium dentifrice. *Acta Odontol Scand*. 1985 Mar;43(1):47-52
- Lo Muzio L, della Valle A, Mignogna MD, Pannone G, Bucci P, Bucci E, Sciubba J. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. *J Oral Pathol Med* 2001 Nov;30(10):611-7.
- Nolan A, Baillie C, Badminton J, Rudralingham M, Seymour RA. The efficacy of topical hyaluronic acid in the management of recurrent aphthous ulceration. *J Oral Pathol Med* 2006 Sep;35(8):461-5.3
- Porter SR, Al-Johani K, Fedele S, Moles DR. Randomised controlled trial of the efficacy of HybenX in the symptomatic treatment of recurrent aphthous stomatitis. *Oral Dis*. 2009 Mar;15(2):155-61
- Porter S, Scully C. Aphthous ulcers: recurrent. *Clin Evid*. 2005 Jun;(13):1687-94.
- Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. *Cochrane Database of Systematic Reviews* 2011, Issue 7. Art. No.: CD001168. DOI: 10.1002/14651858.CD001168.pub2.
- Ungphaiboon S, Nittayananta W, Vuddhakul V, Maneenuan D, Kietthubthew S, Wongpoowarak W, Phadoongsombat N. Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus. *Am J Health Syst Pharm*. 2005 Mar 1;62(5):485-91.

Medel för lokal smärtlindring

- Epstein JB, et al. Benzydamine HCL for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. *Cancer*. 2001;92:875-85.

Medel vid svampinfektion

- Goins RA, Ascher D, Waecker N, Arnold J, Moorefield E. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. *Pediatr Infect Dis J*. 2002;21:1165-7.
- Taillandier J, Esnault Y, Alemanni M. A comparison of fluconazole oral suspension and amphotericin B oral suspension in older patients with oropharyngeal candidosis. *Multicentre Study Group. Age Ageing*. 2000;29:117-23.
- Stafford GD, Arendorf T, Huggett R. The effect of overnight drying and water immersion on candidal colonization and properties of complete dentures. *J Dent*. 1986;14:52-6.

Medel för premedicinering

- Erlandsson AL, et al. Conscious sedation by oral administration of midazolam in paediatric dental treatment. *Swed Dent J*. 2001;25:97-104.
- Lindh-Stromberg U. Rectal administration of midazolam for conscious sedation of uncooperative children in need of dental treatment. *Swed Dent J*. 2001;25:105-11.
- Jensen B. Benzodiazepine sedation in paediatric dentistry. *Swed Dent J Suppl*. 2002;(153):1-45.
- Eriksson L, Rune J. Dosering av midazolam per os i käkkirurgisk praxis. *Tandläkartidningen* 2001;93:40-42.

Medel vid bakteriell infektion

- Antibiotikaprofylax för att förebygga endokardit i samband med odontologiska ingrepp. *Tandläkartidningen* 2016;4:68.
- Läkemedelsverket. Indikationer för antibiotikaprofylax i tandvården – ny rekommendation. Information från Läkemedelsverket 2012;5:22-35. <https://www.lakemedelsverket.se>
- Läkemedelsverket. Rekommendationer för antibiotikabehandling i tandvården. Information från Läkemedelsverket 2014;1:19-30. <https://www.lakemedelsverket.se>
- National Institute for Health and Care Excellence (NICE). Prophylaxis against infective endocarditis: Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. Issued: March 2008 last modified: September 2015. NICE clinical guideline 64. <https://www.nice.org.uk>
- Rekommendation för antibiotika till patienter som strålbehandlats mot munhålan. *Tandläkartidningen* 2016;5:58-59.
- Socialstyrelsen. National Guidelines for Adult Dental Care 2011. www.socialstyrelsen.se/nationalguidelines (21 november 2016)
- 2015 ESC Guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). *Eur Heart J*. 2015;36(44):3075–128.

Medel vid blödningskomplikation

- Patatianian E, Fugate SE. Hemostatic mouthwashes in anti-coagulated patients undergoing dental extraction. *Ann Pharmacother* 2006;40:2205-10.
- Sindet-Pedersen S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. *N Engl J Med* 1989;320:840-3
- Ramström G, et al. Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. *J Oral Maxillofac Surg* 1993;51:1211-6.

Medel vid herpesvirusinfektion

- Arain N, Paravastu SC, Arain MA. Effectiveness of topical corticosteroids in addition to antiviral therapy in the management of recurrent herpes labialis: a systematic review and meta-analysis. *BMC Infect Dis*. 2015 Feb 21;15:82.
- Chi CC1, Wang SH, Delamere FM, Wojnarowska F, Peters MC, Kanjirath PP. Interventions for prevention of herpes simplex labialis (cold sores on the lips). *Cochrane Database Syst Rev*. 2015 Aug 7;8:CD010095.
- Harmenberg J, Arlander E, Aoki F, Bring J, Darpö B, Levin MJ, Tyring S, Spruance SL; ME-609 Study Group. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patientinitiated clinical trial. *J Am Acad Dermatol*. 2011 Apr;64(4):696.e1-11.

Läkemedelsrelaterad käkbensnekros, MRONJ (Medication-Related Osteonecrosis of the Jaws)

- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. *J Oral Maxillofac Surg*. 2014 Oct;72(10):1938-56.

Referenser Urologi

1. Chapple et al. Eur Urol 2008;54:543
2. Novara et al. Eur Urol 2008; 54:740
3. Kaplan et al. BJU Int 2011; 107:1432
4. Meek et al. Dig Dis Sci 2011; 56:7
5. Paquette et al. J Am Geriatr Soc 2011; 59:1332
6. Roehrborn et al. Urology 1999; 53:581
7. Porst et al. Urology 2013; 82:667
8. Giuliano et al. J Sex Med 2013; 10:857
9. deReike & Klarskov. BJU Int;2004;93:757
10. Fourcade. Prog urol. 2000;10:246
11. Perachino et al. BJU Int 2010 ;105 :648
12. Morote et al. J Urol 2007;178:1290
13. Lenhard et al. Data on file. Sandoz A/S Danmark

Referenser Äldre – särskilda rekommendationer

Socialstyrelsen. 2017. Indikatorer för god läkemedelsterapi hos äldre. Art. No. 2017-6-7. www.socialstyrelsen.se

Orostillstånd hos äldre

NICE. 2011. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults Management in primary, secondary and community care. NICE clinical guideline 113.

SBU. Statens beredning för medicinsk utvärdering. 2005. Behandling av ångestsyndrom. En systematisk litteraturoversikt. Rapportnr 177 (volym 1).

Sömn och äldre

SBU. Statens beredning för medicinsk utvärdering. 2010. Behandling av sömnbesvär hos vuxna. En systematisk litteraturoversikt. Rapportnr 199.

Buscemi et al., The Efficacy and Safety of Exogenous Melatonin for Primary Sleep Disorders A Meta-Analysis. *J Gen Intern Med* 2005; 20:1151–1158.

Kanji S et. al., Pharmacological interventions to improve sleep in hospitalised adults: a systematic review. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/27473952"BMJ Open. 2016 Jul 29;6(7).

Scholtens R.M. et al., Physiological melatonin levels in healthy older people: A systematic review. *Journal of Psychosomatic Research* 86 (2016) 20–27

Vural E. M. S. et.al., Optimal Dosages for Melatonin Supplementation Therapy in Older Adults: A Systematic Review of Current Literature. *Drugs Aging* (2014) 31:441–451.

Depression hos äldre

SBU. Statens beredning för medicinsk utvärdering. 2015. Behandling av depression hos äldre. En systematisk litteraturoversikt. Rapportnr 233.

Taylor WD. Clinical practice. Depression in the elderly. 2014. *N Engl J Med* 371 (13): 1228-36. doi: 10.1056/NEJMcp1402180

Äldre och fysisk aktivitet

Yrkesföreningar för Fysisk aktivitet. FYSS 2015 <http://www.fyss.se/om-fyss-2/fyss-2015/>

Läkemedel och äldre

Annika Kragh et al. Äldres läkemedelsbehandling. Studentlitteratur. 2013.

Grubb A. Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: Simultaneous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and internal quality check. 2010. *Scand J Clin Lab Invest* 2010; 70: 65-70.

Lundgren, C. FAS UT 3. Att utvärdera, ifrågasätta och skonsamt avsluta läkemedelsbehandling. Läke-medelskommittén i Väster-bottens läns lands-ting. 2010. www.fasut.nu

SBU Statens beredning för medicinsk utvärdering. 2009. Äldres läkemedelsanvändning – Hur kan den förbättras? Rapportnr 193.

Socialstyrelsen. 2011. Kvaliteten i äldres läkemedelsanvändning- Läkarens roll. Art. No 2011-6-12. www.socialstyrelsen.se

Socialstyrelsen. 2014. Läkemedelsorsakad sjuklighet hos äldre- Kartläggning och förslag till åtgärder. Art. No 2014-12-13. www.socialstyrelsen.se

Läkemedel och fall

Cameron ID, Murray GR et al. Interventions for preventing falls in older people in nursing care facilities and hospitals (Review). *Cochrane Database Syst Rev* 2010, Issue 1. Art No: CD005465. DOI:10.1002/14651858.CD005465.pub2.

Gillespie LD, Gillespie WJ et al. Interventions for preventing falls in elderly people. *Cochrane Database Syst Rev* 2009; 2; No: CD000340. DOI:10.1002/14651858.CD000340.pub2.

Gillespie LD, Robertson MC et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009, Issue 2. Art No: CD007146. DOI: 10.1002/14651858.CD007146.pub2.

Tinetti ME, Richman D et al. Falls efficacy as a measure of fear of falling. J Gerontol 1990; 45: 239-43.

Urologiska spasmolytika

Chapple C, Khullar V et al. The effects of antimuscarinic treatment in overactive bladder: a systematic review and meta-analysis. Eur Urology 2005;48: 5–26.

Glavind K, Chancellor M. Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity. Int Urogynecol J 2011; 22: 907–17.

Fox C, Richardson K et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 59: 1477-83.

Hijaz A, Rackley R. Treating Overactive Bladder in the Elderly: Side-Effect Profiles of Anticholinergic Drugs. 2011-11-16, from http://www.ger-uro.ru/mod_files/pub_mater/s16/s16.doc

Läkemedelsverket. Behandling av urinträngningar och trängningsinkontinens – överaktiv blåsa. Information från Läkemedelsverket 2011; 22: 12-21.

NICE 2013. Mirabegron for treating symptoms of overactive bladder. NICE technology appraisal guidance 290, from guidance.nice.org.uk/ta290

Referenser Öron

Öron

1. Heslop A, Lildholdt T, Gammelgaard N, Ovesen T. Topical ciprofloxacin is superior to topical saline and systemic antibiotics in the treatment of tympanostomy tube otorrhea in children: the results of a randomized clinical trial. *Laryngoscope*. 2010 Dec;120(12):2516-20.
2. SBU. Rörbehandling vid inflammation i mellanörat. En systematisk litteraturoversikt. Stockholm: Statens beredning för medicinsk utvärdering (SBU); 2008. SBU-rapport nr 189. ISBN 978-91-85413-22-5.
3. van Dongen TM, van der Heijden GJ, Venekamp RP, Rovers MM, Schilder AG. A trial of treatment for acute otorrhea in children with tympanostomy tubes. *N Engl J Med* 2014 Feb 20;370(8):723-33. Bakgrundsdokumentation. Uppdatering av behandlings-rekommendation rörotit. Juni 2018. Tillhör Behandlingsrekommendation diagnostik, behandling och uppföljning av akut mediaotit från 2010.
4. "Uppdatering av behandlingsrekommendation rörotit", Läkemiddelverket, juni 2018
5. "Diagnostik, behandling och uppföljning av akut mediaotit - ny rekommendation". Läkemiddelverket, behandlingsrekommendationer 2010:(21)5, uppdaterad juni 2018.